Heterocyclic monoacylglycerol lipase (MAGL) inhibitors

Abstract

The present application relates to a compound of general formula (I) TIFF2022540367000085.tif25169 The present invention relates to heterocyclic compounds of the formula (I), their preparation process, pharmaceutical compositions containing them, and their medical uses. The compounds act as inhibitors of monoacylglycerol lipase (MAGL) and are useful in the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, or psychiatric disorders.

Description

[Technical field]

[0001] The present invention relates to organic compounds useful for therapy or prevention in mammals, in particular monoacylglycerol lipase (MAGL) inhibitors for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, psychiatric disorders, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, and / or depression in mammals. [Background technology]

[0002] Endocannabinoids (ECs) are signaling lipids that exert their biological effects by interacting with the cannabinoid receptors (CBRs), CB1 and CB2. They regulate multiple physiological processes, including neuroinflammation, neurodegeneration, and tissue regeneration (Iannotti, FA et al., Progress in lipid research (2016) 62:107-28). In the brain, the main endocannabinoid, 2-arachidonoylglycerol (2-AG), is produced by diacylglycerol lipase (DAGL) and hydrolyzed by monoacylglycerol lipase, MAGL. MAGL hydrolyzes 85% of 2-AG. The remaining 15% is hydrolyzed by ABHD6 and ABDH12 (Nomura, DK et al., Science (2011) 334:809). MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes, and microglial cells (Chanda, PK, et al., Molecular pharmacology (2010) 78:996; Viader, A., et al., Cell reports (2015) 12:798). Hydrolysis of 2-AG leads to the formation of arachidonic acid (AA), a precursor of prostaglandins (PGs) and leukotrienes (LTs). The oxidative metabolism of AA is increased in inflamed tissues. There are two major enzymatic pathways of oxygenation of arachidonic acid involved in the inflammatory process: cyclooxygenase, which produces PGs, and 5-lipoxygenase, which produces LTs. Among the various cyclooxygenase products formed during inflammation, PGE2 is one of the most important. These products have been detected at the site of inflammation, for example in the cerebrospinal fluid of patients suffering from neurodegenerative disorders, and are thought to contribute to the inflammatory response and disease progression. Mice lacking MAGL (Mgll- / -) have dramatically reduced 2-AG hydrolase activity and elevated 2-AG levels in the nervous system, while other arachidonoyl-containing phospholipid and neutral lipid species, including anandamide (AEA) and other free fatty acids, are unchanged.Conversely, the levels of AA and AA-derived prostaglandins, as well as other eicosanoids, including prostaglandin E2 (PGE2), D2 (PGD2), F2 (PGF2), and thromboxane B2 (TXB2), are strongly decreased. Although the phospholipase A2 (PLA2) enzyme has been considered the major source of AA, cPLA2-deficient mice have unaltered AA levels in their brains, reinforcing the important role of MAGL in the brain for regulating AA production and brain inflammatory processes.

[0003] Neuroinflammation is a common pathological feature of brain diseases, including but not limited to neurodegenerative diseases (e.g., multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, and psychiatric disorders such as anxiety and migraine). In the brain, production of eicosanoids and prostaglandins controls the neuroinflammatory process. The inflammatory inducer lipopolysaccharide (LPS) produces a robust and time-dependent increase in brain eicosanoids that is significantly blunted in Mgll- / - mice. LPS treatment also induces a widespread increase in inflammatory cytokines, including interleukin-1-a (IL-1-a), IL-1b, IL-6, and tumor necrosis factor-a (TNF-a), which is prevented in Mgll- / - mice.

[0004] Neuroinflammation is characterized by the activation of innate immune cells of the central nervous system, microglia, and astrocytes. It has been reported that anti-inflammatory agents can suppress glial cell activation and disease progression, including Alzheimer's disease and multiple sclerosis, in preclinical models (Lleo A., Cell Mol Life Sci. (2007) 64:1403). Importantly, genetic and / or pharmacological disruption of MAGL activity also inhibits LPS-induced activation of brain microglial cells (Nomura, DK et al., Science (2011) 334:809).

[0005] Moreover, genetic and / or pharmacological disruption of MAGL activity has been shown to be protective in several animal models of neurodegeneration, including, but not limited to, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. For example, irreversible MAGL inhibitors have been widely used in preclinical models of neuroinflammation and neurodegeneration (Long, JZ, et al., Nature Chemical Biology (2009) vol. 5, p. 37). Systemic administration of such inhibitors recapitulated the Mgll- / - mouse phenotype in the brain, including increased 2-AG levels, decreased AA levels and related eicosanoid production, and prevention of cytokine production and microglial activation following LPS-induced neuroinflammation (Nomura, DK, et al., Science (2011) vol. 334, p. 809), altogether validating MAGL as a druggable target.

[0006] Following genetic and / or pharmacological disruption of MAGL activity, endogenous levels of MAGL natural substrate, 2-AG, in the brain are increased. 2-AG has been reported to have beneficial effects on pain, for example, by antinociceptive effects in mice (Ignatowska-Jankowska B. et al., J. Pharmacol. Exp. Ther., 2015, vol. 353, p. 424) and psychiatric disorders such as depression in chronic stress models (Zhong P. et al., Neuropsychopharmacology, 2014, vol. 39, p. 1763).

[0007] Furthermore, oligodendrocytes (OLs) and their precursor cells (OPCs), which are myelinating cells in the central nervous system, express cannabinoid receptor 2 (CB2) on their membranes. 2-AG is an endogenous ligand for CB1 and CB2 receptors. It has been reported that both cannabinoids and pharmacological inhibition of MAGL attenuate the vulnerability of OLs and OPCs to excitotoxic injury and thus may be neuroprotective (Bernal-Chico, A. et al., "Glia" (2015) Vol. 63, p. 163). In addition, pharmacological inhibition of MAGL increases the number of myelinating OLs in mouse brains, suggesting that MAGL inhibition may promote the differentiation of OPCs in myelinating OLs in vivo (Alpar, A. et al., "Nature communications" (2014) Vol. 5, p. 4421). Inhibition of MAGL has also been shown to promote remyelination and functional recovery in a mouse model of progressive multiple sclerosis (Feliu A. et al., Journal of Neuroscience (2017) Vol. 37, No. 35, p. 8385).

[0008] Finally, in recent years, metabolism, especially lipid metabolism, has been given importance in cancer research. Researchers believe that de novo fatty acid synthesis plays an important role in tumor development. Many studies have shown that endocannabinoids have antitumorigenic effects, including antiproliferative, apoptosis-inducing, and anti-metastatic effects. MAGL, as a key degradative enzyme for both lipid metabolism and the endocannabinoid system, further contributes to different aspects of tumorigenesis as part of gene expression signatures (Qin, H. et al., Cell Biochem. Biophys. (2014) Vol. 70, p. 33; Nomura DK et al., Cell (2009) Vol. 140, no. 1, p. 49-61; Nomura DK et al., Chem. Biol. (2011) Vol. 18, no. 7, p. 846-856).

[0009] In conclusion, inhibition of MAGL action and / or activation is a promising new therapeutic strategy for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, and psychiatric disorders. Furthermore, inhibition of MAGL action and / or activation is a promising new therapeutic strategy for providing neuroprotection and myelin regeneration. Therefore, there is a high unmet medical need for new MAGL inhibitors. Summary of the Invention

[0010] In a first aspect, the present invention provides a compound of formula (I): [ka] [In the formula, R 1 ~R 3 are as defined herein. or a pharma- ceutically acceptable salt thereof.

[0011] In a further aspect, the present invention provides a process for preparing a compound of formula (I) as described herein, comprising the steps of: (a) Amine 12 or 14: [ka] [In the formula, R 2 is as defined herein, and R 3 is hydroxy (12) or hydrogen (14). of, Carboxylic Acid 15: [ka] [In the formula, R 1 is as defined herein. and, In the presence of a coupling reagent such as HATU, DCC, EDCI, HOBt, TBTU or T3P and a base such as Huenig's base, triethylamine or DMAP, R 3is hydroxy or hydrogen, and optionally 3 provided that is hydroxy; (b) Alcohol R 3 is alkylated by treatment with a suitable base such as NaH, KH, NaHMDS, LiHMDS or LDA, preferably NaH, followed by addition of an electrophile, e.g., an alkyl or cycloalkyl halide such as MeI, EtI, iPrI or CyPrI, to give R 3 is alkoxy or cycloalkyloxy; or (c)R 3 A compound of formula (I) in which R is hydroxy may be reacted with (i) an acid, such as HCl, HBr, HI, POCl3, SOCl2 or PBr3; or (ii) a suitable aminosulfurane reagent, such as DAST; or (iii) a sulfonylating reagent, such as mesyl chloride, followed by reaction of the intermediate sulfonate ester with a halide, such as NaF, to give the alcohol R 3 Convert to halogen and R 3 is halogen. The present invention provides a process including:

[0012] In a further aspect, the present invention provides a compound of formula (I) as described herein when prepared according to the process described herein.

[0013] In a further aspect, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use as a therapeutically active substance.

[0014] In a further aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, and a therapeutically inert carrier.

[0015] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for inhibiting monoacylglycerol lipase (MAGL) in a mammal.

[0016] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for treating or preventing neuroinflammation, a neurodegenerative disease, pain, cancer and / or a psychiatric disorder in a mammal.

[0017] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

[0018] In a further aspect, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in a method of inhibiting monoacylglycerol lipase in a mammal.

[0019] In a further aspect, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prophylaxis of neuroinflammation, a neurodegenerative disease, pain, cancer and / or a psychiatric disorder in a mammal.

[0020] In a further aspect, the present invention provides a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

[0021] In a further aspect, the invention provides the use of a compound of formula (I), as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for inhibiting monoacylglycerol lipase in a mammal.

[0022] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of neuroinflammation, a neurodegenerative disease, pain, cancer and / or a psychiatric disorder in a mammal.

[0023] In a further aspect, the present invention provides the use of a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or spasticity associated with pain in a mammal.

[0024] In a further aspect, the present invention provides a method for inhibiting monoacylglycerol lipase in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0025] In a further aspect, the present invention provides a method for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or psychiatric disorders in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0026] In a further aspect, the present invention provides a method for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or spasticity associated with pain in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] definition It should be understood that any feature, integer, property, compound, chemical moiety or group described in connection with a particular aspect, embodiment or example of the invention is applicable to any other aspect, embodiment or example described herein, except where incompatible. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of any of the foregoing embodiments. The invention extends to any novel one or any novel combination of features disclosed in this specification (including any accompanying claims, abstract and drawings), or any novel one or any novel combination of steps of any method or process so disclosed.

[0028] The term "alkyl" refers to a monovalent or polyvalent, e.g., monovalent or divalent, linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms ("C1-C6-alkyl"), e.g., 1, 2, 3, 4, 5 or 6 carbon atoms. In some embodiments, an alkyl group comprises 1 to 3 carbon atoms, e.g., 1, 2 or 3 carbon atoms. Some non-limiting examples of alkyl include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, iso-butyl, sec-butyl, tert-butyl and 2,2-dimethylpropyl. A particularly preferred, but non-limiting example of alkyl is methyl.

[0029] The term "alkoxy" refers to an alkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom. In some preferred embodiments, an alkoxy group is an alkyl group having 1 to 6 carbon atoms, "C 1-6 In other embodiments, alkoxy groups contain 1-4 carbon atoms. In yet other embodiments, alkoxy groups contain 1-3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, 1,1-dimethylpropoxy, 2,2-dimethylpropoxy, and tert-butoxy. A particularly preferred, but non-limiting example of alkoxy is methoxy.

[0030] The term "halogen" or "halo" refers to fluoro (F), chloro (Cl), bromo (Br) or iodo (I). Preferably, the term "halogen" or "halo" refers to fluoro (F), chloro (Cl) or bromo (Br). Particularly preferred, but non-limiting examples of "halogen" or "halo" are fluoro (F) and chloro (Cl).

[0031] As used herein, the term "cycloalkyl" refers to an alkyl group having 3 to 14 ring carbon atoms ("C 3-12"-cycloalkyl" refers to a saturated or partially unsaturated monocyclic or bicyclic hydrocarbon group, preferably of 3 to 12 ring carbon atoms, more preferably of 3 to 10 ring carbon atoms, even more preferably of 3 to 8 ring carbon atoms, and most preferably of 3 to 6 ring carbon atoms. In some preferred embodiments, the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms. "Bicyclic cycloalkyl" refers to cycloalkyl moieties (i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms) and spirocyclic moieties (i.e., the two rings are connected through one common ring atom) consisting of two saturated carbocyclic rings sharing two carbon atoms. In one embodiment, the cycloalkyl group is a saturated monocyclic hydrocarbon group of 3 to 6 ring carbon atoms, e.g., 3, 4, 5, or 6 carbon atoms. Some non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and 1-bicyclo[1.1.1]pentanyl.

[0032] The term "heterocyclyl" as used herein refers to a heterocyclyl having 3 to 14 ring atoms (C-C 13"-heterocyclyl") refers to a saturated or partially unsaturated monocyclic or bicyclic, preferably monocyclic, ring system of preferably 5 to 14 ring atoms, more preferably 3 to 8 ring atoms, in which 1, 2 or 3 of the ring atoms are heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. Preferably, 1 to 2 of the ring atoms are selected from N and O, and the remaining ring atoms are carbon. "Bicyclic heterocyclyl" refers to heterocyclic moieties consisting of two rings that share two ring atoms (i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms) and spirocyclic moieties (i.e., the two rings are connected through one common ring atom). Some non-limiting examples of monocyclic heterocyclyl groups include 1,2-dihydropyridin-5-yl, azetidin-3-yl, azetidin-2-yl, 2-azaspiro[3.3]heptan-2-yl, 2,6-diazaspiro[3.3]heptan-2-yl, 2-azaspiro[3.4]octan-2-yl, 5-oxa-2-azaspiro[3.4]octan-2-yl, pyrrolidinyl (e.g., pyrrolidin-1-yl), , thiomorpholino, oxetan-3-yl, oxetan-2-yl, tetrahydrofuranyl (e.g., tetrahydrofuran-2-yl), tetrahydropyranyl (e.g., tetrahydropyran-2-yl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, piperazinyl (e.g., piperazin-1-yl), morpholino, morpholin-2-yl and morpholin-3-yl.

[0033] The term "aryl" refers to an alkyl group having 6 to 14 total ring members ("C 6-14 "-aryl") is preferably a monocyclic, bicyclic, or tricyclic carbocyclic ring system having 6 to 12 ring members, more preferably 6 to 10 ring members, where at least one ring of the system is aromatic. Preferred, but non-limiting examples of aryl include phenyl.

[0034] The term "heteroaryl" refers to a heteroaryl having a total of 5 to 14 ring members ("C 1-13"-heteroaryl") refers to a mono- or polyvalent, monocyclic, bicyclic, or tricyclic, preferably bicyclic, ring system, preferably having 5-12 ring members, more preferably 5-10 ring members, and most preferably 5-6 ring members, in which at least one ring in the system is aromatic and at least one ring in the system contains one or more heteroatoms. Preferably, "heteroaryl" refers to a 5-10 membered heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from O, S, and N. Most preferably, "heteroaryl" refers to a 5-10 membered heteroaryl containing 1-2 heteroatoms independently selected from O and N. Some non-limiting examples of heteroaryl include pyridazinyl (e.g., pyridazin-4-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrimidin-6-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-4-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzoxazol-7-yl, Examples of such radicals include 1H-indazol-3-yl, 1H-indazol-4-yl, oxadiazolyl (e.g., 1,2,4-oxadiazol-3-yl, 1,3,4-oxadiazol-2-yl), pyrazolyl (e.g., 1H-pyrazol-4-yl), triazolyl (e.g., 1H-1,2,4-triazol-3-yl, 1H-triazol-4-yl, 2H-triazol-4-yl), and tetrazolyl (e.g., 2H-tetrazol-5-yl).

[0035] The term "cycloalkyloxy" refers to a cycloalkyl group, as defined above, attached to the parent molecular moiety through an oxygen atom.

[0036] The term "hydroxy" refers to an --OH group.

[0037] The term "amino" refers to the group --NH.

[0038] The term "oxo" refers to a double-bonded oxygen (=O).

[0039] The term "alkoxycarbonyl" refers to the group alkyl-OC(O)- (commonly referred to as a "carboxylic acid ester"), where alkyl is as defined herein.

[0040] The term "carboxy" refers to the group -C(O)OH, commonly referred to as "carboxylic acid."

[0041] The term "alkenyl" refers to a monovalent or divalent linear or branched hydrocarbon group of 2 to 6 carbon atoms containing at least one C-C double bond (e.g., 1 or 2 C-C double bonds) ("C2-C6-alkenyl"). In certain embodiments, an alkenyl has 2 to 4 carbon atoms with at least one C-C double bond (e.g., 1 or 2 C-C double bonds). Examples of alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl (e.g., (Z)-but-1-enyl), iso-butenyl, allyl, 2-methylallyl, 2-methylprop-1-enyl, and propa-1,2-dienyl.

[0042] The term "hydroxycycloalkyl" refers to a cycloalkyl group, as defined herein, in which at least one of the hydrogen atoms of the cycloalkyl group is replaced with a hydroxy group. Preferably, "hydroxycycloalkyl" refers to a cycloalkyl group in which one, two or three hydrogen atoms of the alkyl group, most preferably one hydrogen atom, are replaced by a hydroxy group. A preferred, but non-limiting example of a hydroxycycloalkyl group is hydroxycyclopropyl (e.g., 1-hydroxycyclopropyl).

[0043] The term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of the free base or free acid, without being biologically or otherwise undesirable. Salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid (especially hydrochloric acid), and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine, and the like. These salts may also be prepared by addition of an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, and magnesium salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins, etc. A particular pharma- ceutically acceptable salt of the compound of formula (I) is the hydrochloride salt.

[0044] The term "protecting group" (PG) refers to a group that selectively blocks a reactive site in a polyfunctional compound so that a chemical reaction, in the sense conventionally associated with synthetic chemistry, can be selectively carried out at an otherwise unprotected reactive site. The protecting group can be removed at the appropriate time. Exemplary protecting groups are amino-protecting, carboxy-protecting or hydroxy-protecting groups. Particular protecting groups are tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn). Further particular protecting groups are tert-butoxycarbonyl (Boc) and fluorenylmethoxycarbonyl (Fmoc). A more particular protecting group is tert-butoxycarbonyl (Boc). Exemplary protecting groups and their uses in organic synthesis are described, for example, in "Protective Groups in Organic Chemistry," TW Greene and PGM Hutts, 5th Edition (2014), John Wiley & Sons, New York.

[0045] The compounds of formula (I) may contain several asymmetric centers and may exist in the form of optically pure enantiomers, mixtures of enantiomers, such as racemates, optically pure diastereoisomers, mixtures of diastereoisomers, racemates of diastereoisomers or racemic mixtures of diastereoisomers.

[0046] According to the Cahn-Ingold-Prelog rules, the asymmetric carbon atom can be of the "R" or "S" configuration.

[0047] The abbreviation "MAGL" refers to the enzyme monoacylglycerol lipase. The terms "MAGL" and "monoacylglycerol lipase" are used interchangeably herein.

[0048] The term "treatment" as used herein includes (1) inhibiting a condition, disorder or symptom (e.g., arresting, reducing or delaying the onset of a disease or, in the case of maintenance treatment, the recurrence of the disease, the onset of at least one clinical or subclinical symptom of the disease); and / or (2) alleviating symptoms (i.e., causing the regression of the condition, disorder or symptom, or at least one of its clinical or subclinical symptoms). The benefit to the patient to be treated is either statistically significant or at least discernible to the patient or the physician. However, it will be understood that when a pharmaceutical agent is administered to a patient to treat a disease, the result may not necessarily be an effective treatment.

[0049] The term "prophylaxis" as used herein includes preventing or delaying the appearance of clinical symptoms of a condition, disorder or condition in a mammal, particularly a human, who may be affected by or predisposed to being affected by a condition, disorder or condition, but who has not yet experienced or exhibited clinical or subclinical symptoms of the condition, disorder or condition.

[0050] The term "neuroinflammation" as used herein relates to acute and chronic inflammation of nervous tissue, which are the major tissue components of two parts of the nervous system: the brain and spinal cord of the central nervous system (CNS) and the branching peripheral nerves of the peripheral nervous system (PNS). Chronic neuroinflammation is associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Acute neuroinflammation usually occurs soon after injury to the central nervous system, for example as a result of traumatic brain injury (TBI).

[0051] The term "traumatic brain injury" (also known as "TBI", "intracranial injury") relates to damage to the brain due to an external mechanical force, such as rapid acceleration or deceleration, impact, blast wave, or penetration by a projectile.

[0052] The term "neurodegenerative disease" refers to diseases associated with the progressive loss of neuronal structure or function, including neuronal death. Examples of neurodegenerative diseases include, but are not limited to, multiple sclerosis, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

[0053] The term "mental disorder" (also called mental illness or mental disorder) refers to a behavior or mental pattern that can cause distress or impaired functioning in life. Such characteristics may occur as persistent, relapsing, and remitting or single episodes. Examples of mental disorders include, but are not limited to, anxiety and depression.

[0054] The term "pain" refers to unpleasant sensory and emotional experiences associated with actual or potential tissue damage. Examples of pain include, but are not limited to, nociceptive pain, chronic pain (including idiopathic pain), neuropathic pain including chemotherapy-induced neuropathy, phantom limb pain, and syphilitic pain. A particular example of pain is neuropathic pain, which is caused by injury or disease affecting any part of the nervous system involved in bodily sensations (i.e., the somatosensory system). In one embodiment, the "pain" is neuropathic pain resulting from amputation or thoracotomy. In one embodiment, the "pain" is chemotherapy-induced neuropathy.

[0055] The term "neurotoxicity" refers to toxicity in the nervous system. It occurs when exposure to natural or man-made toxic substances (neurotoxins) alters the normal activity of the nervous system, causing damage to nervous tissue. Examples of neurotoxicity include, but are not limited to, exposure to substances used in chemotherapy, radiation therapy, drug therapy, drug abuse, and organ transplantation, as well as neurotoxicity resulting from exposure to heavy metals, certain foods and food additives, pesticides, industrial and / or cleaning solvents, cosmetics, and some naturally occurring substances.

[0056] The term "cancer" refers to diseases characterized by the presence of a neoplasm or tumor, resulting from the abnormal and uncontrolled proliferation of cells (such cells are "cancer cells"). As used herein, the term cancer expressly includes, but is not limited to, hepatocellular carcinoma, colon carcinoma, and ovarian cancer.

[0057] As used herein, the term "mammal" includes both human and non-human animals, including, but not limited to, humans, non-human primates, canines, felines, murines, bovines, equines, and porcines. In a particularly preferred embodiment, the term "mammal" refers to a human.

[0058] Compounds of the Invention In a first aspect (A1), the present invention provides a compound of formula (I): [ka] [In formula: R 1 teeth, (I C 1-6 -alkoxy, halogen and [ka] C6-C optionally substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) Halogen, hydroxy, C 1-6 -alkoxy, -B(OH)2, 5-6 membered heteroaryl, C 1-6 - a 5-6 membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo is selected from the group consisting of R 2 teeth, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C optionally substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; (iv) halogens, C 1-6 -Alkyl, halo-C 1-6 - a 5-14 membered heteroaryl optionally substituted with 1-3 substituents independently selected from alkyl, and oxo; (v) halogens, C 1-6 -Alkyl, halo-C 1-6 -5-14 membered heteroaryloxy optionally substituted with 1-3 substituents independently selected from alkyl, alkyl, and oxo; and (vi) halogens, C 1-6 -Alkyl, halo-C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from alkyl and oxo is selected from the group consisting of R 3 is hydrogen, halogen, C 1-6 -Alkoxy, C 3-14 -cycloalkyloxy, and hydroxy; R 4 is hydrogen, halogen, C 1-6 -Alkyl, Hydroxy-C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -Alkoxycarbonyl-NH-, hydroxy, amino, carboxy, C 1-6 -Alkyl-C(O)-NH-, C 2-6 -Alkenyl-C(O)-NH-, carboxy-NH-, oxo, C 3-14 -Cycloalkyl and hydroxy-C 3-14 -cycloalkyl, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C6-C 14 - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1, 2, 3, or 4. or a pharma- ceutically acceptable salt thereof.

[0059] The invention further provides the following recited embodiment (E) according to the first aspect A1.

[0060] E1 R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C optionally substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) halogens, C 1-6 -Alkoxy, C 1-6 - a 5-6 membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo is selected from the group consisting of R 2 but, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C optionally substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; (iv) halogens, C 1-6 -Alkyl, halo-C 1-6-5-14 membered heteroaryl optionally substituted with 1-3 substituents independently selected from alkyl, aryl, and oxo; and (v) halogens, C 1-6 -Alkyl, halo-C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from alkyl and oxo is selected from the group consisting of R 3 However, hydrogen, halogens, C 1-6 -Alkoxy, C 3-14 -cycloalkyloxy, and hydroxy; R 4 However, hydrogen, halogens, C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -Alkoxycarbonyl-NH-, hydroxy, amino, carboxy, C 1-6 -Alkyl-C(O)-NH-, C 2-6 -Alkenyl-C(O)-NH-, carboxy-NH-, oxo, C 3-14 -Cycloalkyl and hydroxy-C 3-14 -cycloalkyl, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C6-C 14 - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1, 2, 3, or 4; A compound of formula (I) as defined in A1, or a pharma- ceutically acceptable salt thereof.

[0061] E2 A compound of formula (I) according to A1 or E1, or a pharma- ceutically acceptable salt thereof, provided that the compound of formula (I) is (4-Fluorophenyl)-[7-(4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone isn't it).

[0062] E3 A compound of formula (I) according to A1 or E1, or a pharma- ceutically acceptable salt thereof, provided that the compound of formula (I) is (4-Fluorophenyl)-[7-(4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone; hydrochloride; [(7R,9aR)-7-phenyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-methoxyphenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-fluorophenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-chlorophenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-6-methylpyridin-3-yl)methanone; [(7R,9aR)-7-Phenyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-propan-2-yloxyphenyl)methanone; hydrochloride; [(7R,9aR)-7-phenyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-1-methylpyrrolo[2,3-b]pyridin-5-yl)methanone; [(7R,9aR)-7-phenyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-1-propan-2-ylpyrrolo[2,3-b]pyridin-5-yl)methanone; [(7S,9aS)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone; [(7R,9aR)-7-phenyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(3-chloro-2-methoxypyridin-4-yl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-1-methylpyrrolo[2,3-b]pyridin-5-yl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-1-methylpyrazolo[3,4-b]pyridin-5-yl)methanone; [(7R,9aR)-7-(3,4-dichlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone; [(7S,9aS)-7-(3,4-dichlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-bromo-3-methoxyphenyl)methanone; [(7R,9aR)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aS)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-5-methoxypyridin-3-yl)methanone; (4-chloro-3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)-[rac-(7R,9aR)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone; [(7R,9aR)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)methanone; [(7S,9aS)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(4-chloro-3-methyl-[1,2]oxazolo[5,4-b]pyridin-5-yl)methanone; (4-chloro-3-methyl-1H-indazol-5-yl)-[rac-(7R,9aR)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone; (4-chloro-[1,2]thiazolo[5,4-b]pyridin-5-yl)-[rac-(7R,9aR)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone; (4-Chloro-3-methyl-1H-indazol-5-yl)-[rac-(7R,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (4-Chloro-3-methyl-1H-indazol-5-yl)-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(4-chloro-3-methyl-1H-indazol-5-yl)methanone; [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(4-chloro-3-methyl-1H-indazol-5-yl)methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7S,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [2-chloro-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]-[rac-(7R,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [2-chloro-3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-(4-chlorophenyl)-7-fluoro-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-fluoro-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-(4-chlorophenyl)-7-methoxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-methoxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-methyl-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-(6-methoxypyridin-2-yl)methanone; and (6-Amino-4-chloropyridin-3-yl)-[rac-(7R,9aR)-7-(3-chloro-4-fluorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]methanone (not selected from the group consisting of:

[0063] E4 R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) Halogen, hydroxy, C 1-6 -alkoxy, -B(OH)2, 5-6 membered heteroaryl, C 1-6 - a 5-6 membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo A compound of formula (I) according to any one of A1 and E2 to E3, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0064] E5-R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) halogens, C 1-6 -Alkoxy, C 1-6 - a 5-6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo A compound of formula (I) according to any one of A1 and E2 to E3, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0065] E6 R 1 But, C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; or a pharma- ceutically acceptable salt thereof.

[0066] E7 R 1 But, C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14-aryl; or a pharma- ceutically acceptable salt thereof.

[0067] E8 R 1 Chloro, fluoro, methoxy and [ka] or a pharma- ceutically acceptable salt thereof.

[0068] E9 R 1 Chloro, fluoro, methoxy and [ka] or a pharma- ceutically acceptable salt thereof.

[0069] E10 R 2 but, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; (iv) Halo-C 1-6 -5 to 14 membered heteroaryl substituted with alkyl; and (v) 5-14 membered heteroaryloxy substituted with halogen A compound of formula (I) according to any one of A1 and E2 to E9, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0070] E11 R 2 but, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; and (iv) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl A compound of formula (I) according to any one of A1 and E2 to E9, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0071] E12 R 2 but, (i) Halo-C6-C 14 -aryl; and (ii) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl A compound of formula (I) according to any one of A1 and E2 to E9, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0072] E13 R 2 but, (i) chlorophenyl; (ii) 3-chloro-4-fluoro-phenyl; and (iii) CF3-substituted pyridyl A compound of formula (I) according to any one of A1 and E2 to E9, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0073] E14 R 2 but, (iv) chlorophenyl; and (v) CF3-substituted pyridyl A compound of formula (I) according to any one of A1 and E2 to E9, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

[0074] E15 E15 R3 is hydrogen or hydroxy; or a pharma- ceutically acceptable salt thereof.

[0075] E16 E16 R 3 is hydroxy; or a pharma- ceutically acceptable salt thereof.

[0076] E17 R 4 However, hydrogen, halogens, C 1-6 -Alkyl, Hydroxy-C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -A compound of formula (I) according to any one of A1 and E2 to E16, selected from the group consisting of alkoxycarbonyl-NH-, hydroxy and oxo, or a pharma- ceutically acceptable salt thereof.

[0077] E18 R 4 However, hydrogen, halogens, C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -A compound of formula (I) according to any one of A1 and E2 to E16, selected from the group consisting of alkoxycarbonyl-NH-, hydroxy and oxo, or a pharma- ceutically acceptable salt thereof.

[0078] E19 R 4 is selected from the group consisting of hydrogen, halogen, and hydroxy; or a pharma- ceutically acceptable salt thereof.

[0079] E20 R 4 is selected from the group consisting of hydrogen, fluoro, and hydroxy; or a pharma- ceutically acceptable salt thereof.

[0080] E21 A compound of formula (I) according to any one of A1 and E2 to E20, or a pharma- ceutically acceptable salt thereof, wherein L is a covalent bond.

[0081] E22 A compound of formula (I) according to any one of A1 and E2 to E21, wherein A is selected from the group consisting of 5-14 membered heteroaryl and 5-14 membered heterocyclyl, or a pharma- ceutically acceptable salt thereof.

[0082] E23 Compounds of formula (I) according to any one of A1 and E2 to E21, wherein A is selected from the group consisting of pyrazolyl and azetidinyl, or a pharma- ceutically acceptable salt thereof.

[0083] E24 R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) halogens, C 1-6 -Alkoxy, C 1-6 - a 5-6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo is selected from the group consisting of R 2 but, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; and (iv) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl is selected from the group consisting of R 3 is hydrogen or hydroxy; R 4 However, hydrogen, halogens, C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -alkoxycarbonyl-NH-, hydroxy and oxo, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C6-C 14 - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; A compound of formula (I) according to any one of A1 and E2 to E3, or a pharma- ceutically acceptable salt thereof.

[0084] E25 R 1 But, C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl, R 2 but, (i) Halo-C6-C 14 -aryl; and (ii) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl is selected from the group consisting of R 3 is hydroxy, R 4 is selected from the group consisting of hydrogen, halogen, and hydroxy; L is a covalent bond; A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl; Compounds of formula (I) according to A1, E2 and E3, or pharma- ceutically acceptable salts thereof.

[0085] E26 R 1 is chloro, fluoro, methoxy, and [ka] and R 2 but, (i) chlorophenyl; and (ii) CF3-substituted pyridyl is selected from the group consisting of R 3 is hydroxy, R 4 is selected from the group consisting of hydrogen, fluoro, and hydroxy; L is a covalent bond; A is selected from the group consisting of pyrazolyl and azetidinyl; Compounds of formula (I) according to A1, E2 and E3, or pharma- ceutically acceptable salts thereof.

[0086] E27 R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) halogens, C 1-6 -Alkoxy, C 1-6 - a 5-6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo is selected from the group consisting of R 2 but, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; and (iv) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl is selected from the group consisting of R 3 is hydrogen or hydroxy; R 4 However, hydrogen, halogens, C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -alkoxycarbonyl-NH-, hydroxy and oxo, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C6-C 14 - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1 or 2; Compounds of formula (I) according to A1, E2 and E3, or pharma- ceutically acceptable salts thereof.

[0087] E28 R 1 But, C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl, R 2 but, (i) Halo-C6-C 14 -aryl; and (ii) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl is selected from the group consisting of R 3 is hydroxy, R 4 is selected from the group consisting of hydrogen, halogen, and hydroxy; L is a covalent bond; A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl; n is 1 or 2; Compounds of formula (I) according to A1, E2 and E3, or pharma- ceutically acceptable salts thereof.

[0088] E29 R 1 is chloro, fluoro, methoxy, and [ka] and R 2 but, (i) chlorophenyl; (ii) 3-chloro-4-fluoro-phenyl; and (iii) CF3-substituted pyridyl is selected from the group consisting of R 3 is hydroxy, R 4 is selected from the group consisting of hydrogen, fluoro, and hydroxy; L is a covalent bond; A is selected from the group consisting of pyrazolyl and azetidinyl; n is 1 or 2 Compounds of formula (I) according to A1, E2 and E3, or pharma- ceutically acceptable salts thereof.

[0089] E30 The compound of formula (I) [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aS)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone; [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-methoxypyridin-3-yl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(6-amino-2-methylpyridin-3-yl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; 5-[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one; 5-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one; 3-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]-1,3-oxazolidin-2-one; 1-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]imidazolidin-2-one; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-methyl-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aS)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-morpholin-4-ylphenyl)methanone; tert-Butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-piperazin-1-ylphenyl)methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(Z)-2-phenylethenyl]phenyl]methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(E)-2-phenylethenyl]phenyl]methanone; tert-Butyl N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]carbamate; N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide; 4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-hydroxyphenyl)methanone; 4-(3-((7S,9aR)-7-(4-chlorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)-2-fluorophenyl)piperazin-2-one; 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]piperazin-2-one; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)phenyl]methanone; [(7S,9aS)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone; [(7S,9aS)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone; [2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1,2-thiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2,4-thiadiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aS)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone; (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone or a pharma- ceutically acceptable salt thereof.

[0090] E31 The compound of formula (I) [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone; and [(7R,9aR)-7-Hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone or a pharma- ceutically acceptable salt thereof.

[0091] In a further embodiment, the present invention provides a method for producing a pharmaceutical composition comprising: R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) halogens, C 1-6 -Alkoxy, C 1-6 - a 5-6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo is selected from the group consisting of R 4 However, hydrogen, halogens, C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -alkoxycarbonyl-NH-, hydroxy and oxo, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C6-C 14 - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1 or 2; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0092] In a further embodiment, the present invention provides a method for producing a pharmaceutical composition comprising: R 1 but, (I C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl; (ii) halogens, C 1-6 -Alkoxy, C 1-6- a 5-6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogens, C 1-6 -5-14 membered heterocyclyl optionally substituted with 1-3 substituents independently selected from the group consisting of alkyl and oxo is selected from the group consisting of R 4 However, hydrogen, halogens, C 1-6 -Alkyl, C 1-6 -Alkoxycarbonyl, C 1-6 -alkoxycarbonyl-NH-, hydroxy and oxo, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C6-C 14 - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0093] In a preferred embodiment, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: R 1 But, C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl, R 4 is selected from the group consisting of hydrogen, halogen, and hydroxy; L is a covalent bond; A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl; n is 1 or 2; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0094] In a preferred embodiment, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: R 1 But, C 1-6 -alkoxy, halogen and [ka] C6-C substituted with 1 to 2 substituents independently selected from the group consisting of 14 -aryl, R 4 is selected from the group consisting of hydrogen, halogen, and hydroxy; L is a covalent bond; A is selected from the group consisting of 5- to 14-membered heteroaryl and 5- to 14-membered heterocyclyl; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0095] In a particularly preferred embodiment, the present invention comprises: R 1 is chloro, fluoro, methoxy, and [ka] and R 4 is selected from the group consisting of hydrogen, fluoro, and hydroxy; L is a covalent bond; A is selected from the group consisting of pyrazolyl and azetidinyl; n is 1 or 2; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0096] In a particularly preferred embodiment, the present invention comprises: R 1 is chloro, fluoro, methoxy, and [ka] and R 4 is selected from the group consisting of hydrogen, fluoro, and hydroxy; L is a covalent bond; A is selected from the group consisting of pyrazolyl and azetidinyl; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0097] In one embodiment, the present invention provides R 2 but, (i) C optionally substituted with 1 to 3 substituents independently selected from halogen 1-6 -alkyl; (ii) C 3-14 -cycloalkyl; (iii) C6-C substituted with 1 to 2 substituents independently selected from halogen 14 -aryl; and (iv) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl is selected from the group consisting of R 3 is hydrogen or hydroxy; Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0098] In a preferred embodiment, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: R 2 but, (i) Halo-C6-C 14 -aryl; and (ii) Halo-C 1-6 -5-14 membered heteroaryl substituted with alkyl is selected from the group consisting of R 3 is hydroxy, Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0099] In a particularly preferred embodiment, the present invention comprises: R 2 but, (i) chlorophenyl; and (ii) CF3-substituted pyridyl is selected from the group consisting of R 3 is hydroxy, Provided herein is a compound of formula (I), or a pharma- ceutically acceptable salt thereof.

[0100] In one embodiment, the compound of formula (I) has formula (II): [ka] [In formula: (a) B is phenyl; R 2 is phenyl substituted with one or more halogen atoms; R 3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; R 3a is hydrogen or halogen; R 4a teeth, (i) heterocyclyl optionally substituted with a substituent selected from the group consisting of hydroxy, oxo, alkoxycarbonyl, and hydroxycycloalkyl; and (ii) Heteroaryl is selected from the group consisting of R 5a is hydrogen; or (b) B is phenyl; R 2 teeth, (i) heterocyclyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, alkyl, and haloalkyl; (ii) heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, alkyl, and haloalkyl; and (iii) cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, alkyl, and haloalkyl. is selected from the group consisting of R 3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; and R 3a , R 4a and R 5a are independently selected from hydrogen, halogen, alkoxy, and heteroaryl; or (c) B is phenyl; R 2 teeth, [ka] [In the formula, X 1 and X 2 are each independently a halogen. and; R 3 is hydroxy; R 3a , R 4a and R 5a is independently selected from hydrogen, halogen, amino, alkyl, and alkoxy; (d) B is heteroaryl or heterocyclyl; R 2 is phenyl substituted with one or more halogen atoms; R 3 is hydroxy; and R 3a , R 4a and R 5a are independently selected from hydrogen, halogen, alkyl, alkoxy, amino, and oxo; or (e) B is phenyl; R 2 is alkyl or haloalkyl; R 3 is hydroxy; and R 3a , R 4a and R5a is independently selected from hydrogen, halogen, and alkoxy; However, the compound of formula (I) [ka] isn't it] or a pharma- ceutically acceptable salt thereof.

[0101] In one embodiment, the compound of formula (I) has the formula (II): [ka] [In formula: (a) B is phenyl; R 2 is phenyl substituted with one or more halogen atoms; R 3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; R 3a is hydrogen or halogen; R 4a teeth, (i) heterocyclyl optionally substituted with a substituent selected from the group consisting of hydroxy, oxo, alkoxycarbonyl, and hydroxycycloalkyl; and (ii) Heteroaryl is selected from the group consisting of R 5a is hydrogen; or (b) B is phenyl; R 2 teeth, (i) heterocyclyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, alkyl, and haloalkyl; (ii) heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, alkyl, and haloalkyl; and (iii) cycloalkyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, alkyl, and haloalkyl. is selected from the group consisting of R 3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; and R 3a , R 4a and R 5a are independently selected from hydrogen, halogen, alkoxy, and heteroaryl; or (c) B is phenyl; R 2 teeth, [ka] [In the formula, X 1 and X 2 are each independently a halogen. and; R 3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; and R 3a , R 4a and R 5a is independently selected from hydrogen, halogen, amino, alkyl, and alkoxy; (d) B is heteroaryl or heterocyclyl; R 2 is phenyl substituted with one or more halogen atoms; R 3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; and R 3a , R 4a and R 5a are independently selected from hydrogen, halogen, alkyl, alkoxy, amino, and oxo; or (e) B is phenyl; R 2 is alkyl or haloalkyl; R3 is selected from the group consisting of hydrogen, halogen, alkoxy, cycloalkyloxy, and hydroxy; and R 3a , R 4a and R 5a is independently selected from hydrogen, halogen, and alkoxy; However, the compound of formula (I) [ka] TIFF0007669299000031.tif182169 isn't it] or a pharma- ceutically acceptable salt thereof.

[0102] In a preferred embodiment, the present invention relates to a compound of formula (I) having formula (Ia) or (Ib) [ka] The present invention provides a compound of formula (I) as described herein, which is a compound of the formula:

[0103] In one embodiment, the present invention relates to a compound of formula (I) having formula (Ic) or (Id) [ka] The present invention provides a compound of formula (I) as described herein, which is a compound of the formula:

[0104] In certain embodiments, the present invention provides pharma- ceutically acceptable salts, particularly hydrochloride salts, of compounds of formula (I) as described herein. In more particular embodiments, the present invention provides compounds of formula (I) as described herein.

[0105] In some embodiments, compounds of formula (I) are isotopically labeled by replacing one or more atoms therein with an atom having a different atomic mass or mass number. Such isotopically labeled (i.e., radiolabeled) compounds of formula (I) are considered to be within the scope of the present disclosure. Exemplary isotopes that can be incorporated into compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, respectively, e.g. 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, and 125 Certain isotopically labeled compounds of formula (I), for example those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotope tritium, i.e. 3 H and carbon-14, i.e. 14 C are particularly useful for this purpose given their ease of incorporation and ready means of detection. For example, compounds of formula (I) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99% of a given isotope.

[0106] Heavier isotopes, such as deuterium, i.e. 2 Substitutions such as H may confer greater metabolic stability, resulting in, for example, a longer in vivo half-life or lower dosage requirements, which may result in certain therapeutic advantages.

[0107] 11 C. 18 F, 15 O and 13Substitution with positron emitting isotopes, such as N, can be useful in Positron Emission Topography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art, or by processes similar to those described in the Examples set forth below, by substituting the appropriate isotopically labeled reagent for the non-isotopically labeled reagent previously used.

[0108] Manufacturing Process The preparation of the compounds of formula (I) of the present invention can be carried out in sequential or convergent synthetic routes. The synthesis of the present invention is shown in the following general scheme. The techniques required for carrying out the reactions and purification of the obtained products are known to those skilled in the art. The substituents and indices used in the following process descriptions have the meanings given herein, unless otherwise indicated.

[0109] If one of the starting materials, intermediates or compounds of formula (I) contains one or more functional groups that are not stable or reactive under the reaction conditions of one or more reaction steps, suitable protecting groups (e.g. as described in "Protective Groups in Organic Chemistry", TW Greene and PG M Hutts, 5th Edition (2014), John Wiley & Sons, New York) can be introduced prior to a critical step by applying methods well known in the art. Such protecting groups can be removed at a later stage of the synthesis using standard methods described in the literature.

[0110] When the starting material or intermediates contain a stereocenter, the compound of formula (I) can be obtained as a mixture of diastereomers or enantiomers, which can be separated by methods well known in the art, such as chiral HPLC, chiral SFC, or chiral crystallization. Racemic compounds can be separated into their antipodes via diastereomeric salts, for example, by crystallization with optically pure acids, or by separating the antipodes by specific chromatographic methods using either chiral adsorbents or chiral eluents. It is also possible to separate starting materials and intermediates containing a stereocenter to obtain diastereomerically / enantiomerically enriched starting materials and intermediates. The use of such diastereomerically / enantiomerically enriched starting materials and intermediates in the synthesis of the compound of formula (I) typically results in the respective diastereomerically / enantiomerically enriched compound of formula (I).

[0111] Those skilled in the art will recognize that in the synthesis of compounds of formula (I) (unless otherwise desired), an "orthogonal protecting group strategy" can be applied to cleave some protecting groups one at a time without affecting other protecting groups in the molecule. The principle of orthogonal protection is well known in the art and has been described in the literature (e.g., Barany and RB Merrifield, J. Am. Chem. Soc. (1977) 99:7363; H. Waldmann et al., Angew. Chem. Int. Ed. Engl. (1996) 35:2056).

[0112] One skilled in the art will recognize that the reaction sequence may be varied depending on the reactivity and nature of the intermediates.

[0113] More specifically, the compounds of formula (I) can be prepared by the methods shown below, the methods shown in the Examples, or by similar methods. Appropriate reaction conditions for the individual reaction steps are known to those skilled in the art. Also, for reaction conditions described in the literature that affect the reactions described, see, for example, "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", 2nd Edition, Richard C. Larock., John Wiley & Sons, New York, NY (1999)). The reactions could be easily carried out with or without a solvent. There is no particular restriction regarding the nature of the solvent used, provided that it does not adversely affect the reaction or the reagents involved, and that it is capable of dissolving the reagents at least to some extent. The reactions described can take place over a wide range of temperatures, and the exact reaction temperature is not critical to the invention. It is convenient to carry out the reactions described at temperatures ranging from -78°C to reflux. The time required for the reaction can also vary widely, depending on many factors, particularly the reaction temperature and the nature of the reagents. However, a period of 0.5 hours to several days is usually sufficient to produce the intermediates and compounds described. The reaction sequence is not limited to the sequence shown in the scheme, but the order of the reaction steps can be freely changed depending on the starting materials and their respective reactivities.

[0114] In cases where starting materials or intermediates are not commercially available or their synthesis has not been described in the literature, they can be prepared by analogy with existing procedures for analogous materials or as outlined in the experimental section.

[0115] R 1 , R 2 and R 3 is as defined herein, in particular R 3 Compounds of formula (I) where is hydroxy, alkoxy or halogen, more specifically hydroxy, methoxy or F, may be synthesised according to the general procedure outlined in Scheme 1. [ka]

[0116] Thus, PMB-protected secondary amines 6 (which can be obtained, for example, by the general procedure outlined in Scheme 3) can be acylated with the appropriate carboxylic acid 15 using a coupling reagent, for example DCC, HATU, EDCI, HOBt or TBTU, preferably T3P and a base, such as Huenig's base, triethylamine or DMAP, in a suitable solvent, such as N,N-dimethylformamide, DMA, DCM or dioxane, preferably at 0° C. to 50° C. to give the corresponding intermediates 8 (Scheme 1, step a). Removal of the PMB protecting group using acidic conditions, such as treatment with neat AcOH, TfOH, MsOH, TsOH or preferably TFA in a solvent, such as toluene or DCM, optionally in the presence of anisole or 1,3-dimethoxybenzene, preferably in DCM and at a temperature range between room temperature and the boiling point of the reaction mixture, preferably at room temperature, gives the ketone compounds 9 (see, for example, intermediate I-5, step b). Treatment of the ketone intermediate 9 with a phenyl or alkyl Grignard reagent, or trimethyl(trifluoromethyl)silane and TBAF reagent in a solvent such as diethyl ether or THF, preferably THF, and finally in the presence of a Lewis acid such as LiCl, MgCl2, AlCl3, preferably CeCl3, at a temperature range of -78°C to 25°C, preferably 0°C, gives the corresponding compound of formula (I) (R 1 and R 2 is as defined herein, and R 3 is hydroxy) (step c). Alternatively, treatment of a suitable heteroaryl bromide reagent, for example 2-bromo-5-(trifluoromethyl)pyridine, with a solution of n-BuLi in hexane in the presence of ketone intermediate 9 in a solvent such as diethyl ether, THF, toluene or mixtures thereof, preferably toluene, at a temperature range of −78° C. to 25° C., preferably at −78° C., gives the corresponding compound of formula (I) (R 1 and R 2 is as defined herein, and R 3is hydroxy) (step c). The tertiary alcohol moiety of (I) can be further converted to a halogen, preferably F, using conditions known in the art (e.g., in a first step, by reacting (I) with HCl, HBr, HI, POCl3, SOCl2 or PBr3, or with a suitable aminosulfurane reagent such as DAST, or by first converting the alcohol of (I) to a sulfonate ester such as mesylate and subsequently reacting the sulfonate ester with, for example, NaF) to give the compound of formula (I) (R 1 and R 2 is as defined herein, and R 3 is a halogen) can be produced (Scheme 1, step d). 3 Compounds of formula (I) where R is one halogen can be prepared by methods known in the art. 3 The tertiary alcohol moiety of (I) may be further converted to an alkoxy, preferably methoxy, by treatment with a suitable base, such as NaH, KH, NaHMDS, LiHMDS or LDA, preferably NaH, in a solvent such as DMF, THF, dioxane or mixtures thereof, preferably DMF, at a temperature range of −78° C. to room temperature, preferably at 0° C., followed by addition of an electrophile, such as an alkyl or cycloalkyl halide, such as MeI, EtI, iPrI or CyPrI, to give the corresponding compound of formula (I) (R 1 and R 2 As defined herein, R 3 is methoxy) can be obtained (Scheme 1, step e).

[0117] Or, R 1 , R 2 and R 3 is as defined herein, in particular R 3 Compounds of formula (I) where is hydroxy, halogen or alkoxy, more specifically hydroxy, F or methoxy, may be synthesised according to the general procedure outlined in Scheme 2a. [ka]

[0118] Thus, treatment of the protected ketone intermediate 10 (which can be obtained, for example, by the general procedure outlined in Scheme 3), in which PG is a protecting group, for example Boc (see, for example, intermediate I-1), with a phenyl or alkyl Grignard reagent or trimethyl(trifluoromethyl)silane and TBAF reagent in a solvent such as diethyl ether or THF, preferably THF, and finally in the presence of a Lewis acid such as LiCl, MgCl2, AlCl3, preferably CeCl3, at a temperature range of -78°C to 25°C, preferably 0°C, gives the corresponding intermediate 11 (R 1 and R 2 is as defined herein, and R 3 is hydroxy) to give the corresponding intermediate 11 (Scheme 2a, step a). Alternatively, treatment of a suitable heteroaryl bromide reagent such as 2-bromo-5-(trifluoromethyl)pyridine (see, for example, Intermediate I-4A) or 5-bromo-2-(trifluoromethyl)pyridine with a solution of n-BuLi in hexane in the presence of the protected ketone intermediate 10 in a solvent such as diethyl ether, THF, toluene or mixtures thereof, preferably toluene, at a temperature range of −78° C. to 25° C., preferably −78° C., gives the corresponding intermediate 11 (R 1 and R 2 is as defined herein, and R 3 is hydroxy) (Scheme 2a, step a). Removal of the BOC protecting group under appropriate conditions, for example using acidic conditions, for example treatment with HCl in a solvent such as EtOAc or MeOH or with TFA in DCM, preferably at about room temperature, gives the amine intermediate 12 (step b, see for example intermediate I-2A). R can then be converted to amine intermediate 13 by using a coupling reagent such as DCC, EDCI, HOBt, TBTU, T3P, preferably HATU, and a base such as Huenig's base, triethylamine or DMAP, in an appropriate solvent such as N,N-dimethylformamide, DMA, DCM or dioxane, preferably at 0° C. to room temperature. 1An amide coupling reaction with carboxylic acid compound 15, where R is as defined herein, can be accomplished to give compounds of formula (I) (Scheme 2a, step c). The tertiary alcohol moiety of (I) can be further converted to a halogen, preferably F, using conditions known in the art (e.g., in a first step, by reacting (I) with HCl, HBr, HI, POCl3, SOCl2 or PBr3, or with a suitable aminosulfurane reagent such as DAST, or by first converting the alcohol of (I) to a sulfonate ester such as mesylate and subsequently reacting the sulfonate ester with, for example, NaF) to give compounds of formula (I) (R 1 and R 2 is as defined herein, and R 3 is a halogen) can be produced (Scheme 2a, step d). 3 Compounds of formula (I) where R is one halogen can be prepared by methods known in the art. 3 The tertiary alcohol moiety of (I) may be further converted to an alkoxy, preferably methoxy, by treatment with a suitable base, such as NaH, KH, NaHMDS, LiHMDS or LDA, preferably NaH, in a solvent such as DMF, THF, dioxane or mixtures thereof, preferably DMF, at a temperature range of −78° C. to room temperature, preferably at 0° C., followed by addition of an electrophile, such as an alkyl or cycloalkyl halide, such as MeI, to give the corresponding compound of formula (I) (R 1 and R 2 As defined herein, R 3 is methoxy) can be obtained (Scheme 2a, step e).

[0119] Or, R 1 , R 2 and R 3 is as defined herein, in particular R 3 Compounds of formula (I) where is hydrogen may be synthesised according to the general procedure outlined in Scheme 2b. [ka]

[0120] Finally, LiCl, MgCl, AlCl, etc. can be prepared by using phenyl or alkyl Grignard reagents in a solvent such as diethyl ether or THF, preferably THF. 3、 Treatment of the protected ketone intermediate 10 (which can be obtained, for example, by the general procedure outlined in Scheme 3), where PG is a protecting group, for example Boc (see, for example, intermediate I-1), in the presence of a Lewis acid, preferably CeCl, at a temperature range of −78° C. to 25° C., preferably 0° C., affords the corresponding intermediate 11 (R 1 and R 2 is as defined herein, and R 3 is hydroxy) to give the corresponding intermediate 11 (Scheme 2b, step a). Alternatively, treatment of an appropriate heteroaryl bromide reagent such as 2-bromo-5-(trifluoromethyl)pyridine (see, for example, Intermediate I-4A) with a solution of n-BuLi in hexane in the presence of the protected ketone intermediate 10 in a solvent such as diethyl ether, THF, toluene or mixtures thereof, preferably toluene, at a temperature range of −78° C. to 25° C., preferably −78° C., gives the corresponding intermediate 11 (R 1 and R 2 is as defined herein, and R 3 is hydroxy) is obtained (Scheme 2b, step a).

[0121] Following dehydration of the hydroxy intermediate and concomitant cleavage of the protecting group PG, in a solvent such as DCM, MeOH, EtOH, toluene or mixtures thereof, preferably DCM, in the presence of an acid such as HCl, TsOH or MsOH, preferably MsOH, at a temperature range between 0° C. and the boiling point of the solvent, preferably at room temperature, the enamine intermediate 13 is obtained (Scheme 2b, step b). Subsequent heterogeneous catalytic hydrogenation of the alkene using a transition metal catalyst such as PtO2 or Pd / C in the presence of MgO, preferably PtO2, in a solvent such as THF, MeOH, EtOH, EtOAc, preferably THF, in the presence of AcOH at about room temperature and under a hydrogen pressure of 4 bar, gives the amine intermediate 14 (Scheme 2b, step c, see for example intermediate I-6). Finally, R can be prepared by using a coupling reagent such as DCC, EDCI, HOBt, TBTU, T3P, preferably HATU, and a base such as Huenig's base, triethylamine or DMAP in a suitable solvent such as N,N-dimethylformamide, DMA, DCM or dioxane, preferably at 0° C. to room temperature. 1 An amide coupling reaction can be accomplished with carboxylic acid compound 15, wherein R is as defined herein, to give compounds of formula (I) (step d).

[0122] Intermediates 6 and 10 can be synthesized by a variety of conditions, which can be exemplified by the general procedure outlined in Scheme 3. [ka]

[0123] Starting from commercially available 3-bromo-6-pyridinecarbonitrile (1), a nucleophilic aromatic substitution reaction can be carried out with 4-methoxybenzyl alcohol in the presence of a suitable base, such as NaOH, KOH, KH, preferably with NaH, in a solvent such as DMF, THF, dioxane or mixtures thereof, preferably in a mixture of DMF and THF, preferably at a temperature range of 0° C. to room temperature to give the corresponding PMB-protected compound 2 (Scheme 3, step a). Reduction of the nitrile group can be achieved using a suitable reducing agent such as borane, lithium borohydride or lithium aluminum hydride in a solvent such as ether, DME, THF or mixtures thereof, at a temperature range of 0° C. to the boiling point of the solvent, or by using catalytic hydrogenation conditions such as Raney nickel, preferably in a solvent such as MeOH, in the presence of ammonium hydroxide, at about 50° C. and 3.5 bar under a hydrogen atmosphere to give the corresponding amine 3 (Scheme 3, step b). Subsequent amide coupling reaction with bromoacetic acid using a suitable coupling agent such as DCC, DCI or preferably EDCI in a solvent such as DCM, THF, DMF, DCE or CH3CN, preferably DCM, at a temperature range between 0°C and the boiling point of the solvent, preferably at room temperature, gives the amide compound 4a (Scheme 3, step c). Subsequent heating of intermediate 4a in a solvent such as EtOH, MeOH, preferably CH3CN, preferably at about 50°C, gives the pyridinium intermediate 4b (Scheme 3, step d). After treatment with a suitable reducing agent, such as sodium borohydride in a solvent such as MeOH, preferably at about 100°C, the lactam compound 5 is obtained (Scheme 3, step d'). Reduction of the amide with a suitable reducing agent, such as borane, lithium borohydride or preferably lithium aluminum hydride, in a solvent such as ether, DME or a mixture thereof, preferably THF, at a temperature range between 0°C and the boiling point of the reaction mixture, preferably under reflux, gives the corresponding amine compound 6 (Scheme 3, step e).After removal of the PMB protecting group using acidic conditions such as treatment with neat AcOH, TfOH, MsOH, TsOH or preferably TFA in a solvent such as toluene or DCM, optionally in the presence of anisole or 1,3-dimethoxybenzene, preferably in DCM and at a temperature range between room temperature and the boiling point of the reaction mixture, preferably at room temperature, the ketone compound 7 (Scheme 3, step f). Finally, the secondary amine of 7 is protected with a suitable protecting group (Scheme 3, step g) to give intermediate 10. Thus, for example, treatment with di-tert-butyl dicarbonate in a suitable solvent such as CH3CN, DCM, dioxane or THF, preferably in CH3CN, at a temperature range between 0°C and room temperature, preferably at room temperature, optionally in the presence of a base such as DMAP, TEA, NaHCO3 or preferably Na2CO3, gives the Boc-protected ketone intermediate I-1.

[0124] In one embodiment, carboxylic acid compound 15 is an intermediate of type A, B or C. For example, intermediates of type A, B and C can be prepared as illustrated by the synthetic procedure outlined in Scheme 4. [ka]

[0125] B is aryl, especially phenyl, X is halogen, preferably bromine or triflate, R y The ester compound 40, where R is halogen or alkoxy, can be converted to R by applying a cross-coupling reaction such as Buchwald-Hartwig cross-coupling. x is an N-linked heterocycle. Treatment of intermediate 40 with a suitable amine, such as azetidin-3-ol or morpholine, in a suitable solvent, such as dioxane or toluene, in the presence of a base, such as CsCO or KPO, at temperatures ranging from room temperature to the boiling point of the solvent, using a suitable catalytic system, such as Pd(dba) or Pd(OAc) and xantphos, dabephos or BINAP, and optionally applying microwave heating, provides the ester compound 41 (Scheme 4, step a).

[0126] Or X, B and R y The ester compound 40, wherein R is as defined above, can be converted to R by applying the Suzuki cross-coupling reaction. x can be converted to intermediate 51, which is a C-bonded heterocycle, by reaction with a suitable catalyst (e.g., bis(triphenylphosphine)palladium(II) chloride with triphenylphosphine, dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct, tetrakis(triphenylphosphine)palladium(0) or tetrakis(triphenylphosphine)palladium(II) chloride ... dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium(II) chloride, dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium(II) chloride, dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium(II) chloride, dichloro[1,1'-bis(diphenylphosphino) Treatment of intermediate 40 with an appropriate boronic acid or ester, such as a heterocyclylboronic acid or ester, such as tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate or tert-butyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate using palladium(II) acetate affords the ester compound 51 (Scheme 4, step a).

[0127] B is aryl, particularly phenyl; X is a boronic acid or boronic ester; R y The ester compound 50, where R is an alkoxy or halogen, can be converted to an ester of R by applying the Suzuki cross-coupling reaction. xcan be converted to intermediate 51, which is a C-linked heterocycle. Treatment of intermediate 50 with a suitable organic halide or triflate, for example a bromo-substituted heteroaryl, such as 4-bromo-3-fluoro-1H-pyrazole, in a suitable solvent (e.g., dioxane, DME, water, toluene, DMF or mixtures thereof) and a suitable base (e.g., Na2CO3, NaHCO3, KF, K2CO3 or NEt3), at a temperature between room temperature and the boiling point of the reaction mixture, using a suitable catalyst (e.g., bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II), bis(triphenylphosphine)palladium(II) chloride, dichloro[1,1'-bis(diphenylphosphino)-ferrocene]palladium(II) dichloromethane adduct, tetrakis(triphenylphosphine)palladium(0) or palladium(II) acetate with triphenylphosphine), optionally with microwave heating, provides ester compound 51 (Scheme 4, step a).

[0128] B is aryl, in particular phenyl, X is halogen selected from iodine, bromine and chlorine, preferably iodine, R y C 1-6 The ester compound 60, where R is -alkoxy or halogen, can be converted to R by applying a cross-coupling reaction such as Ullmann cross-coupling. x can be converted to intermediate 61, which is an amide-linked heterocycle. Treatment of intermediate 60 with a suitable building block bearing an amide motif, for example a cyclic urea or carbamate, such as an imidazolidin-2-one or oxazolidin-2-one, using a suitable catalytic system, such as copper(I) iodide and N,N'-dimethylethane-1,2-diamine, in the presence of a base, such as CsCO3 or K2CO3, in a suitable solvent, such as dioxane or acetonitrile, at temperatures ranging from room temperature to the boiling point of the solvent, gives ester compound 61 (Scheme 4, step a).

[0129] Finally, alkaline hydrolysis of the ester moiety of intermediates 41, 51 or 61 with a suitable base, such as aqueous lithium hydroxide, sodium hydroxide or potassium hydroxide, preferably lithium hydroxide, in a solvent such as MeOH, EtOH, THF or mixtures thereof at a temperature range between 0° C. and the boiling point of the reaction mixture, preferably around room temperature, gives intermediates of type A, B or C (Scheme 4, step b).

[0130] In one aspect, the present invention provides a process for making a compound of formula (I) as depicted in any one of the schemes disclosed herein.

[0131] In a further aspect, the present invention provides a process for preparing a compound of formula (I) as described herein, comprising the steps of: (a) Compound 9 [ka] [In the formula, R 1 is as defined herein], Organolithium Reagent R 2 Li or organomagnesium reagent R 2 MgX, where X is a halogen, to give a tertiary alcohol of formula (I) (R 2 is as defined herein, and R 3 is hydroxy; and, optionally, (b) Alcohol R 3 is alkylated by treatment with a suitable base such as NaH, KH, NaHMDS, LiHMDS or LDA, preferably NaH, followed by addition of an electrophile, e.g. an alkyl or cycloalkyl halide such as MeI, EtI, iPrI or CyPrI, to give the corresponding compound of formula (I), 3 is alkoxy or cycloalkyloxy; or (c)R 3A compound of formula (I) in which R is hydroxy may be reacted with (i) an acid, such as HCl, HBr, HI, POCl3, SOCl2 or PBr3; or (ii) a suitable aminosulfurane reagent, such as DAST; or (iii) a sulfonylating reagent, such as mesyl chloride, followed by reaction of the intermediate sulfonate ester with a halide, such as NaF, to give the alcohol R 3 Convert to halogen and R 3 and forming the corresponding compound of formula (I) in which The present invention provides a process including:

[0132] In a further aspect, the present invention provides a process for preparing a compound of formula (I) as described herein, comprising the steps of: (a) Amine 12 or 14: [ka] [In the formula, R 2 is as defined herein, and R 3 is hydroxy (12) or hydrogen (14). of, Carboxylic Acid 15: [ka] [In the formula, R 1 is as defined herein. and, In the presence of a coupling reagent such as HATU, DCC, EDCI, HOBt, TBTU or T3P and a base such as Huenig's base, triethylamine or DMAP, R 3 is hydroxy or hydrogen, and optionally 3 provided that is hydroxy; (b) Alcohol R 3is alkylated by treatment with a suitable base such as NaH, KH, NaHMDS, LiHMDS or LDA, preferably NaH, followed by addition of an electrophile, e.g., an alkyl or cycloalkyl halide such as MeI, EtI, iPrI or CyPrI, to give R 3 is alkoxy or cycloalkyloxy; or

[0133] (c)R 3 A compound of formula (I) in which R is hydroxy may be reacted with (i) an acid, such as HCl, HBr, HI, POCl3, SOCl2 or PBr3; or (ii) a suitable aminosulfurane reagent, such as DAST; or (iii) a sulfonylating reagent, such as mesyl chloride, followed by reaction of the intermediate sulfonate ester with a halide, such as NaF, to give the alcohol R 3 Convert to halogen and R 3 is halogen; The present invention provides a process including:

[0134] In a further aspect, the present invention provides a compound of formula (I) as described herein when prepared according to any one of the processes described herein.

[0135] MAGL inhibitory activity The compounds of the present invention are MAGL inhibitors. Thus, in one aspect, the present invention provides the use of a compound of formula (I) as described herein for inhibiting MAGL in a mammal.

[0136] In a further aspect, the invention provides a compound of formula (I) as described herein for use in a method of inhibiting MAGL in a mammal.

[0137] In a further aspect, the invention provides the use of a compound of formula (I) as described herein for the preparation of a medicament for inhibiting MAGL in a mammal.

[0138] In a further aspect, the present invention provides a method for inhibiting MAGL in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein.

[0139] Compounds were profiled for MAGL inhibitory activity by determining the enzymatic activity following hydrolysis of the natural substrate 2-arachidonoylglycerol (2-AG) to yield arachidonic acid, which may be followed by mass spectrometry. This assay is hereinafter abbreviated as "2-AG assay."

[0140] The 2-AG assay was performed in a total volume of 20 μL in 384-well assay plates (PP, Greiner, Cat. No. 784201). Compound dilutions were made in 3-fold dilution steps in polypropylene plates in 100% DMSO (VWR Chemicals 23500.297) to give a final concentration range in the assay of 12.5 μM to 0.8 pM. 0.25 μL of compound dilution (100% DMSO) was added to 9 μL of MAGL in assay buffer (50 mM TRIS (GIBCO, 15567-027), 1 mM EDTA (Fluka, 03690-100ml), 0.01% (v / v) Tween). After shaking, the plate was incubated at room temperature for 15 min. To start the reaction, 10 μL of 2-arachidonoylglycerol in assay buffer was added. The final concentrations in the assay were 50 pM MAGL and 8 μM 2-arachidonoyl glycerol. After shaking and incubation at room temperature for 30 min, the reaction was quenched by adding 40 μL of ACN containing 4 μM d8-arachidonic acid. The amount of arachidonic acid was followed using an online SPE system (Agilent Rapidfire) in combination with a triple quadrupole mass spectrometer (Agilent 6460). A C18 SPE cartridge (G9205A) was used in an ACN / water liquid setup. The mass spectrometer was operated in negative electrospray mode, following the mass transitions 303.1→259.1 for arachidonic acid and 311.1→267.0 for d8-arachidonic acid. The activity of the compounds was calculated based on the intensity ratio (arachidonic acid / d8-arachidonic acid).

[0141] [Table 1] TIFF0007669299000043.tif216165 TIFF0007669299000044.tif223165 TIFF0007669299000045.tif237165 TIFF0007669299000046.tif188165 TIFF0007669299000047.tif229165 TIFF0007669299000048.tif207165 TIFF0007669299000049.tif224165 TIFF0007669299000050.tif199165 TIFF0007669299000051.tif198165 TIFF0007669299000052.tif221165 TIFF0007669299000053.tif237165 TIFF0007669299000054.tif216165

[0142] In one aspect, the present invention provides compounds of formula (I) and their pharma- ceutically acceptable salts or esters as described herein, wherein the compounds of formula (I) and their pharma- ceutically acceptable salts or esters have an IC for MAGL inhibition as measured in the MAGL assay as described herein. 50 is less than 25 μM, preferably less than 10 μM, more preferably less than 5 μM.

[0143] In one embodiment, the compounds of formula (I) and their pharma- ceutically acceptable salts or esters as described herein have an IC 50 (MAGL inhibition) values ​​range from 0.000001 μM to 25 μM, and certain compounds have IC 50 The IC value is 0.000005 μM to 10 μM, and more specific compounds have IC 50 The value is 0.00005μM to 5μM.

[0144] Uses of the Compounds of the Invention In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use as a therapeutically active substance.

[0145] In a further aspect, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for treating or preventing neuroinflammation, a neurodegenerative disease, pain, cancer and / or a psychiatric disorder in a mammal.

[0146] In one embodiment, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for treating or preventing a neuroinflammatory and / or neurodegenerative disease in a mammal.

[0147] In one embodiment, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for treating or preventing a neurodegenerative disease in a mammal.

[0148] In one embodiment, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for treating or preventing cancer in a mammal.

[0149] In one aspect, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

[0150] In a preferred embodiment, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of multiple sclerosis, Alzheimer's disease and / or Parkinson's disease in a mammal.

[0151] In a particularly preferred embodiment, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the treatment or prevention of multiple sclerosis in a mammal.

[0152] In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prophylaxis of neuroinflammation, a neurodegenerative disease, pain, cancer and / or a psychiatric disorder in a mammal.

[0153] In one embodiment, the invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of a neuroinflammatory and / or neurodegenerative disease in a mammal.

[0154] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of cancer in a mammal.

[0155] In one embodiment, the invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of a neurodegenerative disease in a mammal.

[0156] In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

[0157] In a preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of multiple sclerosis, Alzheimer's disease and / or Parkinson's disease in a mammal.

[0158] In a particularly preferred embodiment, the present invention provides a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of multiple sclerosis in a mammal.

[0159] In one aspect, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of neuroinflammation, a neurodegenerative disease, pain, cancer and / or a psychiatric disorder in a mammal.

[0160] In one embodiment, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for treating or preventing a neuroinflammatory and / or neurodegenerative disease in a mammal.

[0161] In one embodiment, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for treating or preventing a neurodegenerative disease in a mammal.

[0162] In one embodiment, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for treating or preventing cancer in a mammal.

[0163] In a further aspect, the present invention provides the use of a compound of formula (I) as defined herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain and / or spasticity associated with pain in a mammal.

[0164] In a preferred embodiment, the invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of multiple sclerosis, Alzheimer's disease and / or Parkinson's disease in a mammal.

[0165] In a particularly preferred embodiment, the present invention provides the use of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof, for the preparation of a medicament for the treatment or prevention of multiple sclerosis in a mammal.

[0166] In one aspect, the invention provides a method for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer and / or psychiatric disorders in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0167] In one embodiment, the present invention provides a method for the treatment or prevention of a neuroinflammatory and / or neurodegenerative disease in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0168] In one embodiment, the present invention provides a method for the treatment or prevention of a neurodegenerative disease in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0169] In one aspect, the present invention provides a method for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression and / or pain in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0170] In a preferred embodiment, the present invention provides a method for the treatment or prevention of multiple sclerosis, Alzheimer's disease and / or Parkinson's disease in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0171] In a particularly preferred embodiment, the present invention provides a method for the treatment or prevention of multiple sclerosis in a mammal, the method comprising administering to the mammal an effective amount of a compound of formula (I) as described herein, or a pharma- ceutically acceptable salt thereof.

[0172] Pharmaceutical Compositions and Administration In one aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as described herein and a therapeutically inert carrier.

[0173] The compounds of formula (I) and their pharma- ceutically acceptable salts and esters can be used as medicines (e.g., in the form of pharmaceutical preparations). Pharmaceutical preparations can be administered to the body orally (e.g., in the form of tablets, coated tablets, dragees, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g., in the form of nasal drops), or rectally (e.g., in the form of suppositories). However, administration can also be parenterally, such as intramuscularly or intravenously (e.g., in the form of injections).

[0174] The compound of formula (I) and its pharma- ceutically acceptable salts and esters can be treated with pharma- ceutically inert inorganic or organic adjuvants for the preparation of tablets, coated tablets, sugar-coated tablets, and hard gelatin capsules.Lactose, corn starch or its derivatives, talc, stearic acid or its salts, etc., can be used as adjuvants for tablets, sugar-coated tablets, and hard gelatin capsules, for example.

[0175] Suitable adjuvants for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semisolid substances, and liquid polyols.

[0176] Suitable adjuvants for the production of solutions and syrups are, by way of example, water, polyols, saccharose, invert sugar, glucose etc.

[0177] Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils etc.

[0178] Suitable adjuvants for suppositories are, by way of example, natural or hardened oils, waxes, fats, semisolid or liquid polyols etc.

[0179] Furthermore, the pharmaceutical preparations may contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, salts for varying the osmotic pressure, buffers, masking agents, or antioxidants. The pharmaceutical preparations of the present invention may further contain other therapeutically valuable substances.

[0180] Dosage can vary widely and will of course be adapted to the individual requirements in each particular case. In general, for oral administration, a daily dosage of about 0.1 mg to 20 mg / kg body weight, preferably about 0.5 mg to 4 mg / kg body weight (e.g., about 300 mg / person) will be appropriate, preferably divided into 1 to 3 individual doses, which may be composed of, for example, the same amount. However, it is clear that the upper limit given in this specification can be exceeded, if indicated. EXAMPLES

[0181] The present invention will be more fully understood by reference to the following examples, which should not, however, be construed as limiting the scope of the claims to the examples.

[0182] Where the preparations are obtained as mixtures of enantiomers, the pure enantiomers can be separated by the methods described herein or by methods known to those skilled in the art, such as chiral chromatography (e.g., chiral SFC) or crystallization.

[0183] Unless otherwise noted, all reactions and intermediates were prepared under an argon atmosphere.

[0184] Abbreviation AcOH = acetic acid, aq. = aqueous, Boc = tert-butyloxycarbonyl, BINAP = 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, BnBr = benzyl bromide, n-BuLi = n-butyllithium, n-BuOH = butanol, CAS RN = Chemical Abstracts Registry Number, CHCl3 = chloroform, CyPrI = cyclopropyl iodide, Davephos = 2-dicyclohexylphosphino-2'-(N,N-dimethylamino)biphenyl, DAST = diethylaminosulfur trifluoride, DCM = dichloromethane, DCE = 1,2-dichloroethane, DCC = N,N'-dicyclohexylcarbodiimide, DIC = N,N'-diisopropylcarbodiimide, DMA = N,N-dimethylacetamide, DMAP = 4-dimethylaminopyridine, DME = dimethoxyethane, DMF = N,N-dimethylformamide, EDCI = N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, EtOAc = ethyl acetate, EtOH = ethanol, EtI = ethyl iodide, HATU = O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, HCl = hydrogen chloride, HPLC = high performance liquid chromatography, HOBt = 1-hydroxybenzotriazole, Huenig base = iPr2NEt = N-ethyldiisopropylamine, iPrI = isopropyl iodide, K2CO3 = potassium carbonate, KH = potassium hydride, LDA = lithium diisopropylamide, LiHMDS = lithium bis(trimethylsilyl)amide, L-selectride = lithium tri-sec-butyl(hydrido)borate, MeOH = methanol, RT = room temperature, MeI = methyl iodide, MS = mass spectrum, MsOH = methylsulfonic acid, NaH = sodium hydride, NaHCO3 = sodium bicarbonate, Na2CO3 = sodium carbonate, NaHMDS = sodium bis(trimethylsilyl)amide, NaOH = sodium hydroxide, Na2SO4 = sodium sulfate, NH4Cl = ammonium chloride, sat.= saturated, Pd / C = palladium on activated carbon, Pd(OH)2 = palladium hydroxide = Pearlman catalyst, PtO2 = platinum dioxide, PE = petroleum ether, PMB = 4-methoxybenzyl ether, SFC = supercritical fluid chromatography, TBAF = tetra-n-butylammonium fluoride, TBTU = O-benzotriazol-1-yl-N,N,N',N'-tetramethyl-uronium tetrafluoroborate, TEA = triethylamine, TFA = trifluoroacetic acid, Tf2NPh = N-phenyltrifluoromethanesulfonimide, Tf2O = trifluoromethanesulfonic anhydride, TfOH = triflic acid, THF = tetrahydrofuran, TsOH = paratoluenesulfonic acid, T3P = propylphosphonic anhydride, Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.

[0185] Intermediate I-1 tert-Butyl 7-oxo-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate

[0186] Step [A] 5-[(4-methoxyphenyl)methoxy]pyridine-2-carbonitrile To a solution of (4-methoxyphenyl)methanol (75.5 g, 546.4 mmol) in DMF (1000 mL) cooled to 0° C., 65% NaH dispersion in mineral oil (32.8 g, 819.6 mmol) was added in portions and the mixture was stirred at this temperature for 30 min. Then, 3-bromo-6-pyridinecarbonitrile (CAS RN 97483-77-7, 100.0 g, 546.4 mmol) was added in portions and the reaction mixture was stirred at room temperature for 2 h. The mixture was poured into saturated aqueous NH4Cl (3000 mL), filtered and washed with EtOAc (3×200 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the crude title compound (112 g, 85.3%) as a pink solid; MS (ESI): m / z=241.1 [M+H] + .

[0187] Step [B] [5-[(4-methoxyphenyl)methoxy]-2-pyridyl]methanamine To a solution of 5-[(4-methoxyphenyl)methoxy]pyridine-2-carbonitrile (50.0 g, 208.1 mmol) in methanol (2000 mL) was added Raney nickel (10.0 g, 170.4 mmol) followed by ammonium hydroxide (20.0 mL, 266.7 mmol). The reaction mixture was then stirred for 50 min under a 3.5 bar H2 atmosphere. o C for 12 h. The mixture was filtered and the resulting filtrate was concentrated in vacuo to give the crude title compound (50 g, 98.3% yield) as a dark red solid; MS (ESI): m / z=245.3 [M+H] + .

[0188] Step [C] 2-Bromo-N-[[5-[(4-methoxyphenyl)methoxy]-2-pyridyl]methyl]acetamide To a solution of [5-[(4-methoxyphenyl)methoxy]-2-pyridyl]methanamine (43.6 g, 178.5 mmol) in DCM (200 mL) cooled to 0° C., EDCI (34.1 g, 178.5 mmol) was added in small portions followed by bromoacetic acid (24.8 g, 178.5 mmol) and the reaction mixture was stirred at room temperature for 1 h. The mixture was poured into saturated aqueous NaHCO3 (200 mL). The organic layer was separated and washed with more saturated aqueous NaHCO3 (3×50 mL), brine (50 mL), dried over Na2SO4 and concentrated in vacuo to give the crude title compound (60.6 g, 93% yield) as a dark red oil: m / z=367.2 [M+2] +

[0189] Step [D] 7-[(4-methoxyphenyl)methoxy]-1,2,4,6,9,9a-hexahydropyrido[1,2-a]pyrazin-3-one 2-Bromo-N-[[5-[(4-methoxyphenyl)methoxy]-2-pyridyl]methyl]acetamide (11.60 g, 31.76 mmol, 1 equiv.) was dissolved in CH3CN (150 mL) and diluted with 50 oThe mixture was concentrated in vacuo to remove the solvent and the residue was redissolved in MeOH (150 mL) and cooled to 0° C. Sodium borohydride (12.01 g, 317.5 mmol) was then carefully added to the reaction mixture, which was stirred at room temperature for 12 h. The mixture was evaporated to dryness and the residue was purified by silica gel flash chromatography eluting with a gradient of 1-10% MeOH in DCM to give the crude product. This material was then triturated with EtOAc (50 mL), filtered and further dried under high vacuum to give the title compound (3.1 g, 33.9%) as a yellow solid; MS (ESI): m / z=289.1 [M+H] + .

[0190] Step [E] 7-[(4-methoxyphenyl)methoxy]-2,3,4,6,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine To a solution of 7-[(4-methoxyphenyl)methoxy]-1,2,4,8,9,9a-hexahydropyrido[1,2-a]pyrazin-3-one (3.10 g, 10.7 mmol) in THF (100 mL) cooled to 0 °C, LiAlH4 (1.02 g, 26.9 mmol) was carefully added and the reaction mixture was stirred for 80 min for 2 h. o The mixture was heated to 0° C. The mixture was cooled to 0° C. and quenched with water (4 mL) and 20% saturated aqueous NaHCO3 (4 mL). The mixture was filtered, washed with THF (3×20 mL), and the resulting filtrate was concentrated in vacuo to give the crude title compound (2.9 g, 98%) as a yellow solid; MS (ESI): m / z=275.3 [M+H] + .

[0191] Step [F] tert-Butyl 7-oxo-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate To a solution of 7-[(4-methoxyphenyl)methoxy]-2,3,4,6,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine (1 g, 3.93 mmol) in DCM (50 mL) was added TFA (10.0 mL, 10.57 mmol) and the reaction mixture was stirred at room temperature for 1 h. The mixture was concentrated in vacuo to remove the solvent and the residue was redissolved in CH3CN (50 mL) and cooled to 0 °C. Na2CO3 (3.3 g, 31.13 mmol) was then added followed by di-tert-butyl dicarbonate (6.8 g, 31.1 mmol) and the reaction mixture was stirred at room temperature for 12 h. The mixture was diluted with water (100 mL) and extracted with EtOAc (3x100 mL). The combined organic layers were washed with water (3x30 mL), brine (50 mL), dried over Na2SO4 and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with 10-30% EtOAc in PE to give the title compound (2.62 g, 99.3%) as a pale yellow solid.

[0192] Intermediates I-2A and I-2B (7S,9aR)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol and (7R,9aS)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol

[0193] Step [A] tert-Butyl rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate To a solution of tert-butyl 7-oxo-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate (intermediate I-1, 1 g, 3.93 mmol) in THF (65 ml) cooled to 0° C., a 1 M solution of 4-chlorophenylmagnesium bromide in THF (7.08 ml, 7.08 mmol) was added dropwise while maintaining the temperature at 0-1° C., and the reaction mixture was then stirred at room temperature for 3 h. The mixture was diluted with EtOAc, poured into saturated aqueous NH4Cl, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash chromatography eluting with a 30-100% EtOAc-heptane gradient to give the title compound (0.295 g, 20%) as a red oil; MS (ESI): m / z=367.2 [M+H] + .

[0194] Step [B] (7S,9aR)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol and (7R,9aS)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol To a solution of tert-butyl rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate (0.8 g, 2.18 mmol) in dioxane (5 mL) cooled to 0° C., 4 M HCl in dioxane (5.45 mL, 21.8 mmol) was added and the reaction mixture was stirred at room temperature for 15 h. The resulting suspension was diluted with EtOAc, poured slowly into cold saturated aqueous Na2CO3, and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was subjected to chiral SFC separation to give (7S,9aR)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (Intermediate I-2A, 0.195 g, 32%) and (7R,9aS)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (Intermediate I-2B, 0.190 g, 31%) as orange semi-solids, respectively; MS (ESI): m / z=267.2 [M+H] + .

[0195] Intermediates I-3A and I-3B (7S,9aR)-7-(3-chloro-4-fluoro-phenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol and (7R,9aS)-7-(3-chloro-4-fluoro-phenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol

[0196] Intermediates I-3A and I-3B were prepared similarly to intermediates I-2A and I-2B, except that in step [A], a 0.5 M solution of 3-chloro-4-fluorophenylmagnesium bromide (CAS RN 413589-34-1) in THF was used to give the title compounds, respectively, as yellow oils; MS (ESI): m / z=285.1 [M+H] + .

[0197] Intermediate I-4A (7R,9aR)-7-[5-(trifluoromethyl)-2-pyridyl]-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol

[0198] Step [A] tert-Butyl rac-(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)-2-pyridyl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate To a solution of 2-bromo-5-(trifluoromethyl)pyridine (CAS RN 50488-42-1, 1 g, 4.42 mmol) in toluene (14.3 mL) cooled to -78 °C, a 1.6 M solution of nBuLi in hexane (3.04 mL, 4.87 mmol) was added and the mixture was stirred at this temperature for 5 min. Then, a cooled solution of tert-butyl 7-oxo-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate (Intermediate I-1, 1.24 g, 4.87 mmol) in toluene (14 ml) was added dropwise while maintaining the temperature at -78 °C and the reaction mixture was stirred for 1.5 h. The reaction was quenched with saturated aqueous NH4Cl and the mixture was extracted with EtOAc. The combined organics were washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 20-80% EtOAc-heptane gradient to give the title compound (0.817 g, 46%) as a pale yellow viscous oil; MS (ESI): m / z=402.3 [M+H] + .

[0199] Step [B] tert-butyl (7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)-2-pyridyl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate and tert-butyl (7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)-2-pyridyl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate Chiral SFC separation of tert-butyl rac-(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)-2-pyridyl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate afforded (7S,9aS)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (0.326 g, 37%) and (7R,9aR)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (0.252 g, 31%) as light brown solids, respectively; MS(ESI): m / z=402.3[M+H] + .

[0200] Step [C] (7R,9aR)-7-[5-(trifluoromethyl)-2-pyridyl]-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol To a solution of tert-butyl (7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)-2-pyridyl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate (0.25 g, 0.623 mmol) in dioxane (1.5 mL) cooled to 0° C., 4 M HCl in dioxane (1.56 mL, 6.23 mmol) was added and the reaction mixture was stirred at room temperature for 15 h. The mixture was evaporated to dryness to give the crude title compound (Intermediate I-4A, 0.23 g) as a hydrochloride salt as a light brown solid; MS (ESI): m / z=470.2 [M+H] + .

[0201] Intermediate I-4B (7S,9aS)-7-[5-(trifluoromethyl)-2-pyridyl]-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol was prepared similarly to intermediate I-4A, but using tert-butyl (7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)-2-pyridyl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate in step [C] to give the crude title compound as a light brown solid as the hydrochloride salt; MS (ESI): m / z=470.2 [M+H] + .

[0202] Intermediate I-5 2-(2-Chloro-3-methoxybenzoyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-7-one

[0203] Step [A] (2-chloro-3-methoxyphenyl)-[7-[(4-methoxyphenyl)methoxy]-1,3,4,6,9,9a-hexahydropyrido[1,2-a]pyrazin-2-yl]methanone To a solution of 2-chloro-3-methoxybenzoic acid (2.94 g, 15.75 mmol) and 7-[(4-methoxyphenyl)methoxy]-2,3,4,6,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine (Intermediate I-1[E], 3.6 g, 13.12 mmol) in DMF (50 mL) cooled to 0° C., TEA (5.6 mL, 39.36 mmol) was added followed by T3P (9.06 g, 19.68 mmol), and the reaction mixture was then heated to 50° C. for 12 h. The reaction was diluted with water (100 mL) and extracted with EtOAc (2×80 mL). The combined organic layers were washed with water (2×50 mL) and brine (50 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 50-100% EtOAc-heptane gradient to give the title compound (3.9 g, 67.1%) as a yellow solid; MS (ESI): m / z=443.2 [M+H] + .

[0204] Step [B] 2-(2-chloro-3-methoxybenzoyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-7-one To a solution of (2-chloro-3-methoxy-phenyl)-[7-[(4-methoxyphenyl)methoxy]-1,3,4,6,9,9a-hexahydropyrido[1,2-a]pyrazin-2-yl]methanone (3.9 g, 8.8 mmol) in DCM (50 mL) cooled to 0 °C was added TFA (3.39 mL, 44 mmol) and the reaction mixture was then stirred at room temperature for 1 h. The mixture was concentrated in vacuo, the residue was dissolved in EtOAc, poured into saturated aqueous NaHCO3 (100 mL) and the aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated. The residue was purified by silica gel flash chromatography eluting with a 50-100% EtOAc-heptane gradient to give the title compound (2.1 g, 73.9%) as a pale yellow foam. MS(ESI): m / z=341.2 [M+HO+H] + .

[0205] Intermediate I-6 (7R,9aR)-7-(4-chlorophenyl)octahydro-1H-pyrido[1,2-a]pyrazine

[0206] Step [A] tert-Butyl 7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate To a solution of tert-butyl 7-oxo-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate (intermediate I-1, 1.0 g, 3.93 mmol) in THF (30 mL) cooled to 0° C., 4-chlorophenylmagnesium bromide (1 M solution in THF, 7.08 mL, 7.08 mmol) was added and the reaction mixture was stirred at room temperature for 2 h. The mixture was poured into saturated aqueous NH4Cl (100 mL) and extracted with EtOAc (3×50 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica flash chromatography eluting with a 5% to 25% EtOAc-PE gradient to give the title compound (0.820 g, 56.8%) as a pale yellow oil; MS (ESI): m / z=367.1 [M+H] + .

[0207] Step [B] 7-(4-chlorophenyl)-2,3,4,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine To a solution of tert-butyl 7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate (0.820 g, 2.24 mmol) in DCM (25 mL) was added methanesulfonic acid (5.0 mL, 164 mmol) and the reaction mixture was stirred at 20° C. for 18 h. The mixture was poured into saturated aqueous NaHCO3 (100 mL) and extracted with DCM (3×50 mL). The combined organic phases were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo to give the crude title compound (0.560 g) as a pale yellow oil; MS (ESI): m / z=249.1 [M+H] + .

[0208] Step [C] rac-(7R,9aS)-7-(4-chlorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine, (7R,9aR)-7-(4-chlorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine and (7S,9aS)-7-(4-chlorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine To a solution of 7-(4-chlorophenyl)-2,3,4,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine (0.130 g, 0.523 mmol) in THF (2.5 mL) and AcOH (0.250 mL) was added PtO2 (0.025 g, 0.523 mmol) and the mixture was stirred at room temperature under 4 bar H2 pressure for 2 h. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by SFC to give rac-(7R,9aS)-7-(4-chlorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine (peak A, 0.020 g, 14%), (7R,9aR)-7-(4-chlorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine (peak B, 0.018 g, 11%) and (7S,9aS)-7-(4-chlorophenyl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine (peak C, 0.015 g, 9%) as off-white foams, respectively; MS (ESI): m / z=251.2 [M+H] + .

[0209] Intermediate I-7 [3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chloro-phenyl]boronic acid

[0210] To a solution of (7S,9aR)-7-(4-chlorophenyl)octahydro-2H-pyrido[1,2-a]pyrazin-7-ol (Intermediate I-2A, 0.05 g, 0.187 mmol) and 2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (CAS RN 1046153-00-7, 0.053 g, 0.187 mmol) in DMF (1.5 mL) cooled to 0 °C in an ice bath, Hunig's base (0.082 mL, 0.469 mmol) was added followed by HATU (0.086 g, 0.225 mmol) and the reaction mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo and the residue was purified by reverse-phase HPLC to give the title compound (0.065 g, 73%) as a colorless lyophilized powder; MS (ESI): m / z=449.3 [M+H]+.

[0211] Intermediate I-8 (2-Chloro-3-((7R,9aR)-7-hydroxy-7-(5-(trifluoromethyl)pyridin-2-yl)octahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)phenyl)boronic acid was prepared similarly to intermediate I-7, but using (7R,9aR)-7-[5-(trifluoromethyl)-2-pyridyl]-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (intermediate I-4A), to give the crude title compound as a pale yellow solid; MS (ESI): m / z=484.3 [M+H] + .

[0212] Intermediate I-9 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(5-bromo-4-chloropyridin-3-yl)methanone was prepared similarly to intermediate I-7, but using 5-bromo-4-chloronicotinic acid (CAS RN 1256790-85-8) to give the crude title compound as a pale yellow solid; MS (ESI): m / z=486.2 [M+H] + .

[0213] Intermediates I-10A and I-10B (7S,9aR)-7-(3,4-difluorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol and (7R,9aS)-7-(3,4-difluorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol

[0214] Step [A] tert-Butyl rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carboxylate To a solution of tert-butyl 7-oxooctahydro-2H-pyrido[1,2-a]pyrazine-2-carboxylate (Intermediate I-1, 1.5 g, 5.9 mmol) in Me-THF (5 mL) cooled to -20°C was added dropwise a 0.5 M solution of (3,4-difluorophenyl)magnesium bromide (CAS RN 90897-92-0, 13 mL, 6.49 mmol) in Me-THF while maintaining the temperature at -20°C. The reaction mixture was then stirred at room temperature for 4 h. The mixture was diluted with EtOAc, poured into saturated NH4Cl (25 mL) and extracted with EtOAc (2 x 50 mL). The organic layers were combined, washed with brine, dried over sodium sulfate and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a gradient of 10-40% EtOAc in heptane to give the title compound (0.833 g, 38%, 1:3 cis:trans) as a colorless foam; MS (ESI): m / z=385.2 [M+H] + .

[0215] Step [B] (7S,9aR)-7-(3,4-difluorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol and (7R,9aS)-7-(3,4-difluorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol To a solution of tert-butyl 7-(3,4-difluorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-2-carboxylate (0.83 g, 2.25 mmol) in DCM (2.5 mL) cooled to 0° C. in an ice bath, TFA (1.04 mL, 13.5 mmol) was added and the reaction mixture was stirred at room temperature overnight. The cooled mixture was carefully basified by dropwise addition of 2 M aqueous NaOH (7.88 mL, 15.8 mmol) and the resulting aqueous phase was extracted with DCM. The combined organic phases were dried over Na2SO4, filtered and evaporated to dryness. The crude material was purified by SFC to give the cis product (peak A), a mixture of cis and trans products (0.236 g, peak B), and one of (7R,9aS)-7-(3,4-difluorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (intermediate I-10B, 0.160 g, peak C). Peak B was purified a second time by SFC to give (7S,9aR)-7-(3,4-difluorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (intermediate I-10A, 0.160 g, 26%) as an orange oil; MS (ESI): m / z=285.1 [M+H] + .

[0216] Intermediate I-11 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(5-bromo-4-methylpyridin-3-yl)methanone was prepared similarly to intermediate I-7, but using 5-bromo-4-methylnicotinic acid (CAS RN 677702-58-8) to give the crude title compound as a colorless solid; MS (ESI): m / z=464.2 [M+H] + .

[0217] Intermediate A-1 Lithium;2-chloro-3-(3-hydroxyazetidin-1-yl)benzoate

[0218] Step [A] Methyl 2-chloro-3-(3-hydroxyazetidin-1-yl)benzoate In a sealed tube, methyl 3-bromo-2-chlorobenzoate (CAS RN 871224-19-0, 0.1 g, 0.401 mmol), cesium carbonate (0.261 g, 0.802 mmol), Pd2(dba)3 (0.037 g, 0.040 mmol) and Xantphos (23.2 mg, 40.1 μmol, Eq: 0.1) were mixed in dioxane (1 mL). The mixture was degassed with argon, then azetidin-3-ol (CAS RN 45347-82-8, 0.059 g, 0.802 mmol) was added and the reaction mixture was heated to 100 °C for 16 h. The mixture was diluted with EtOAc and washed with water and brine. The organic phase was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 0-50% EtOAc-heptane gradient to give the title compound (0.034 g, 35%) as an orange viscous oil; MS (ESI): m / z=242.1 [M+H]+.

[0219] Step [B] Lithium; 2-chloro-3-(3-hydroxyazetidin-1-yl)benzoate To a solution of methyl 2-chloro-3-(3-hydroxyazetidin-1-yl)benzoate (0.035 g, 0.145 mmol) in THF (0.350 mL) was added 1M aqueous LiOH (0.29 mL, 290 mmol) and the reaction mixture was stirred at room temperature for 5 h. The mixture was concentrated in vacuo and the residue was triturated in diisopropyl ether, filtered off and further dried on high vacuum to give the crude title compound as the lithium salt (0.032 g, 82%) as a light brown solid; MS (ESI): m / z=228.1 [M+H] + .

[0220] Intermediate A-2 Lithium; 2-fluoro-3-(3-hydroxyazetidin-1-yl)benzoate was prepared similarly to intermediate A-1, but using methyl 3-bromo-2-fluorobenzoate (CAS RN 206551-41-9) in step [A] to give the crude title compound as a lithium salt as a yellow solid; MS (ESI): m / z=212.0 [M+H] + .

[0221] Intermediate A-3 2-Chloro-3-(1H-pyrazol-5-yl)benzoic acid

[0222] Step [A] Methyl 2-chloro-3-(1H-pyrazol-5-yl)benzoate In a sealed tube, methyl 3-bromo-2-chlorobenzoate (CAS RN 871224-19-0, 0.6 g, 2.4 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (CAS RN 1256359-17-7, 0.778 g, 2.65 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.169 g, 0.240 mmol) were mixed in DMF (6 mL). The reaction mixture was purged with argon. Then, a 1M aqueous solution of Na2CO3 (7.21 mL, 7.21 mmol) was added and the reaction mixture was heated to 100 °C for 4 h. The mixture was diluted with EtOAc, poured into water and the aqueous layer was extracted with EtOAc. The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 50-100% EtOAc-heptane gradient to give the title compound (0.195 g, 34%) as a yellow solid; MS (ESI): m / z=237.1 [M+H]+.

[0223] Step [B] 2-chloro-3-(1H-pyrazol-5-yl)benzoic acid To a solution of methyl 2-chloro-3-(1H-pyrazol-3-yl)benzoate (0.195 g, 0.824 mmol) in THF (2 mL) was added 1 M aqueous solution of LiOH (1.65 ml, 1.65 mmol) and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was acidified to pH=4 by adding 2 M aqueous HCl (0.8 mL) and the aqueous layer was extracted with Me-THF (2×10 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated to dryness to give the crude title compound (0.144 g, 82%) as a yellow solid; MS (ESI): m / z=223.0 [M+H]+.

[0224] Intermediate A-4 2-Chloro-3-(4-methyl-1H-pyrazol-3-yl)benzoic acid was prepared similarly to intermediate A-3, except that tert-butyl 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (CAS RN 1402174-62-2) was used in step [A] to give the crude title compound as a white solid; MS (ESI): m / z = 237.1 [M + H] + .

[0225] Intermediate A-5 2-Fluoro-3-(4-methyl-1H-pyrazol-3-yl)benzoic acid was prepared similarly to intermediate A-4, but using methyl 3-bromo-2-fluorobenzoate (CAS RN 206551-41-9) in step [A] to give the crude title compound as a white solid; MS (ESI): m / z=221.1 [M+H] + .

[0226] Intermediate A-6 3-(4-Methyl-1H-pyrazol-3-yl)benzoic acid was prepared similarly to intermediate A-4, but using ethyl 3-bromobenzoate (CAS RN 24398-88-7) in step [A] to give the crude title compound as a colorless oil; MS (ESI): m / z=203.0 [M+H] + .

[0227] Intermediate A-7 2-Fluoro-3-morpholinobenzoic acid

[0228] Step [A] Methyl 2-fluoro-3-morpholino-benzoate In a sealed tube, methyl 3-bromo-2-fluorobenzoate (CAS RN 206551-41-9, 0.050 g, 0.215 mmol), morpholine (0.022 mL, 0.257 mmol), K3PO4 (0.091 g, 0.429 mmol) and DavePhos (0.013 g, 0.032 mmol) were combined in toluene (1 mL). The mixture was degassed with argon. Pd2(dba)3 (0.020 g, 0.021 mmol) was then added and the reaction mixture was heated to 80 °C for 15 h. The mixture was evaporated to dryness and the residue was purified by reverse phase HPLC to give the title compound (0.051 g, 19.5%) as a colorless solid; MS (ESI): m / z = 240.1 [M + H] + .

[0229] Step [B] 2-Fluoro-3-morpholinobenzoic acid was prepared similarly to intermediate A-3[B] to give the title compound as a colorless solid; MS (ESI): m / z=226.1 [M+H] + .

[0230] Intermediate A-8 3-(4-tert-butoxycarbonylpiperazin-1-yl)-2-fluoro-benzoic acid

[0231] Step [A] tert-Butyl 4-(2-fluoro-3-(methoxycarbonyl)phenyl)piperazine-1-carboxylate In a sealed tube, methyl 3-bromo-2-fluorobenzoate (CAS RN 206551-41-9, 0.050 g, 0.215 mmol), tert-butyl piperazine-1-carboxylate (0.042 g, 0.225 mmol), Cs2CO3 (0.140 g, 0.429 mmol) were combined in toluene (1 mL). The mixture was degassed with argon. BINAP (0.013 g, 0.021 mmol) was then added followed by Pd2(OAc)2 (0.005 g, 0.021 mmol) and the reaction mixture was heated to 80 °C for 15 h. The mixture was filtered through Dicalite, washed with EtOAc and the solution was concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 0-100% EtOAc-heptane gradient to give the title compound (0.029 g, 35%) as a colorless viscous oil; MS (ESI): m / z=339.2 [M+H]+.

[0232] Step [B] 3-(4-tert-butoxycarbonylpiperazin-1-yl)-2-fluoro-benzoic acid was prepared similarly to intermediate A-3[B] to give the title compound as a yellow solid; MS (ESI): m / z=325.2 [M+H] + .

[0233] Intermediate A-9 2-Fluoro-3-(3-oxopiperazin-1-yl)benzoic acid

[0234] Step [A] Methyl 2-fluoro-3-(3-oxopiperazin-1-yl)benzoate was prepared similarly to intermediate A-1[A], but using 2-piperazinone (CAS RN 5625-67-2), to give the title compound as an off-white solid; MS (ESI): m / z=253.2 [M+H] + .

[0235] Step [B] 2-Fluoro-3-(3-oxopiperazin-1-yl)benzoic acid was prepared similarly to intermediate A-3[B] to give the crude title compound as an off-white solid; MS (ESI): m / z=239.2 [M+H] + .

[0236] Intermediate A-10 2-Chloro-3-(3-oxopiperazin-1-yl)benzoic acid was prepared similarly to intermediate A-9, but using methyl 3-bromo-2-chlorobenzoate (CAS RN 206551-41-9) in step [A] to give the crude title compound as a colorless viscous oil; MS (ESI): m / z=255.2 [M+H] + .

[0237] Intermediate A-11 Lithium; 2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)benzoic acid was prepared similarly to intermediate A-1, but using 6-oxa-1-azaspiro[3.3]heptane (CAS RN 1046153-00-7) in step [A] to give the crude title compound as a lithium salt as a pale yellow solid; MS (ESI): m / z=254.2 [M+H] + .

[0238] Intermediate A-12 2-Chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]benzoic acid was prepared similarly to intermediate A-9, but using (S)-pyrrolidin-3-ol (CAS RN 100243-39-8) in step [A] to give the crude title compound as a light brown foam; MS (ESI): m / z=256.1 [M+H] + .

[0239] Intermediate A-13 2-Chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]benzoic acid was prepared similarly to intermediate A-9, but using (R)-pyrrolidin-3-ol (CAS RN 2799-21-5) in step [A] to give the crude title compound as a brown foam; MS (ESI): m / z=242.1 [M+H] + .

[0240] Intermediate A-14 Lithium; 2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)benzoate was prepared similarly to intermediate A-1, but using 3-methylazetidin-3-ol trifluoroacetate (CAS RN 1104083-24-0) in step [A] to give the crude title compound as the lithium salt as a light brown oil; MS (ESI): m / z=240.2 [M+H] + .

[0241] Intermediate A-15 Lithium;2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]benzoate

[0242] Step [A] Methyl 2-chloro-3-[(3S)-3-hydroxy-1-piperidyl]benzoate was prepared similarly to intermediate A-8, but using (S)-piperidin-3-ol (CAS RN 24211-55-0), to give the title compound as a yellow oil; MS (ESI): m / z=270.1 [M+H] + .

[0243] Step [B] 2-Fluoro-3-(3-oxopiperazin-1-yl)benzoic acid was prepared similarly to intermediate A-1[B] to give the crude title compound as a lithium salt as a white solid; MS (ESI): m / z=256.1 [M+H] + .

[0244] Intermediate A-16 Lithium; 2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]benzoate was prepared similarly to intermediate A-15, but using (R)-piperidin-3-ol (CAS RN 62414-68-0) in step [A] to give the crude title compound as a white solid; MS (ESI): m / z=256.1 [M+H] + .

[0245] Intermediate A-17 Lithium; 2-chloro-3-(4-hydroxypiperidin-1-yl)benzoate was prepared similarly to intermediate A-15, but using piperidin-4-ol (CAS RN 5382-16-1) in step [A] to give the crude title compound as the lithium salt as an off-white powder; MS (ESI): m / z=256.2 [M+H] + .

[0246] Intermediate A-18 Lithium; 2-chloro-3-(3-hydroxy-3-methyl-pyrrolidin-1-yl)benzoate was prepared similarly to intermediate A-1, but using 3-methylpyrrolidin-3-ol (CAS RN 125032-87-3) in step [A] to give the crude title compound as a light brown foam; MS (ESI): m / z=256.1 [M+H] + .

[0247] Intermediate A-19 Lithium; 2-chloro-3-((3S,4S)-3,4-dihydroxypyrrolidin-1-yl)benzoate was prepared similarly to intermediate A-1, but using (3S,4S)-pyrrolidine-3,4-diol (CAS RN 90481-32-6) in step [A] to give the crude title compound as an orange amorphous solid; MS (ESI): m / z=258.1 [M+H] + .

[0248] Intermediate A-20 Lithium; 2-chloro-3-(3-fluoro-3-(hydroxymethyl)azetidin-1-yl)benzoate was prepared similarly to intermediate A-1, but using 3-fluoroazetidin-3-yl)methanol (CAS RN 1268520-93-9) in step [A] to give the crude title compound as a pale yellow solid; MS (ESI): m / z = 260.1 [M + H] + .

[0249] Intermediate A-21 Lithium; 2-chloro-3-(3-(hydroxymethyl)azetidin-1-yl)benzoate was prepared similarly to intermediate A-1, but using azetidin-3-ylmethanol (CAS RN 95849-02-8) in step [A] to give the crude title compound as a pale yellow solid; MS (ESI): m / z=242.1 [M+H] + .

[0250] Intermediate A-22 2-Fluoro-3-(1H-pyrazol-3-yl)benzoic acid

[0251] In a sealed tube, methyl 3-bromo-2-fluorobenzoate (CAS RN 206551-41-9, 0.155 g, 0.665 mmol) and tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (CAS RN 1256359-17-7, 0.215 g, 0.732 mmol) were dissolved in DMF (2 mL). The mixture was degassed with argon for 5 min. Bis(triphenylphosphine)palladium(II) chloride (0.047 mg, 0.066 mmol) was then added, followed by a 1M aqueous solution of Na2CO3 (2 mL, 2 mmol), and the reaction mixture was stirred at 100 °C overnight. The mixture was diluted with EtOAc and washed with H2O. The layers were separated and the aqueous phase was acidified to pH=1 with HCl (25%) and extracted again with EtOAc. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC to give some product (0.005 g). The aqueous layer was evaporated to dryness to give more product (0.025 g). Both materials were combined to give the title compound (0.030 g, 21.9%) as a colorless solid; MS (ESI): m / z=207.1 [M+H]+.

[0252] Intermediate B-1 2-Chloro-3-(3-fluoro-1H-pyrazol-4-yl)benzoic acid

[0253] Step [A] Methyl 2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)benzoate In a microwave vial, methyl 2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS RN 2201133-24-4, 0.162 g, 0.546 mmol), 4-bromo-3-fluoro-1H-pyrazole (CAS RN 1346555-56-3, 0.060 g, 0.364 mmol) and K2CO3 (0.151 g, 1.09 mmol) were mixed in dioxane (7.8 mL) / water (2.6 mL). The reaction mixture was degassed with argon. Bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (CAS RN 887919-35-9, 0.025 g, 0.036 mmol) was then added to the mixture, which was heated to 115 °C for 30 min in a microwave. The mixture was diluted with EtOAc, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with EtOAc. The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 0-50% EtOAc-heptane gradient to give the title compound (0.045 g, 49%) as a pale yellow solid; MS (ESI): m / z = 255.2 [M+H]+.

[0254] Step [B] 3-(3-fluoro-1H-pyrazol-4-yl)benzoic acid was prepared in the same manner as intermediate A-3[B] to give the title compound as a yellow solid. MS (ESI): m / z=241.1 [M+H] + .

[0255] Intermediate B-2 2-Fluoro-3-isothiazol-3-yl-benzoic acid was prepared similarly to intermediate B-1, but using methyl 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS RN 1638847-77-4) and 3-bromoisothiazole (CAS RN 55512-82-8) in step [A] to give the crude title compound as a brown oil; MS (ESI): m / z=224.1 [M+H] + .

[0256] Intermediate B-3 2-Chloro-3-(4-fluoro-1H-pyrazol-5-yl)benzoic acid was prepared similarly to intermediate B-1, but using 3-bromo-4-fluoro-1H-pyrazole (CAS RN 1621526-49-5) in step [A] to give the crude title compound as a yellow oil; MS (ESI): m / z=255.1 [M+H] + .

[0257] Intermediate B-4 Lithium 2-fluoro-3-(1H-pyrazol-5-yl)benzoate

[0258] Step [A] Methyl 2-fluoro-3-(1H-pyrazol-5-yl)benzoate In a sealed tube, K2CO3 (0.412 g, 2.98 mmol), methyl 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (CAS RN 1638847-77-4, 0.334 g, 1.19 mmol), 3-bromo-1H-pyrazole (CAS RN 14521-80-3, 0.146 g, 0.993 mmol) and bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) (CAS RN 887919-35-9, 0.070 g, 0.099 mmol) were mixed in dioxane (5.5 mL) and water (1.8 mL). The mixture was degassed with argon for 5 min. The reaction mixture was heated to 60° C. for 30 min and then to 110° C. for an additional 3 h. The mixture was diluted with EtOAc, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and evaporated. The residue was purified by silica gel flash chromatography eluting with a 0-60% EtOAc-heptane gradient to give the title compound (0.59 g, 27%) as a pale yellow solid; MS (ESI): m / z=221.1 [M+H]+.

[0259] Step [B] Lithium; 2-fluoro-3-(1H-pyrazol-5-yl)benzoate was prepared in the same manner as in Intermediate A-1[B] to give the title compound as a colorless solid. MS (ESI): m / z=207.0 [M+H] + .

[0260] Intermediate B-5 2-Fluoro-3-(4-fluoro-1H-pyrazol-5-yl)benzoic acid was prepared similarly to intermediate B-4, but using 3-bromo-4-fluoro-1H-pyrazole (CAS RN 1621526-49-5) in step [A] to give the crude title compound as a colorless solid; MS (ESI): m / z=225.1 [M+H] + .

[0261] Intermediate B-6 Lithium; 2-chloro-3-(1,2,4-thiadiazol-3-yl)benzoate was prepared similarly to intermediate B-1, but using 3-bromo-1,2,4-thiadiazole (CAS RN 1621526-49-5) in step [A] to give the crude title compound as a colorless solid; MS (ESI): m / z=241.1 [M+H] + .

[0262] Intermediate C-1 2-Chloro-3-(2-oxooxazolidin-3-yl)benzoic acid

[0263] Step [A] Methyl 2-chloro-3-(2-oxooxazolidin-3-yl)benzoate In a sealed tube, methyl 2-chloro-3-iodobenzoate (CAS RN 620621-51-4, 0.2 g, 0.675 mmol), oxazolidin-2-one (0.117 g, 1.35 mmol) and K2CO3 (0.233 g, 1.69 mmol) were mixed in acetonitrile (2 mL). The reaction mixture was purged with argon. N,N'-dimethylethane-1,2-diamine (0.012 g, 0.135 mmol) and copper(I) iodide (0.026 g, 0.135 mmol) were then added and the reaction mixture was heated to 80 °C for 15 h. The mixture was diluted with EtOAc, poured into water and the aqueous layer was extracted with EtOAc. The combined organics were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC to give the title compound (0.036 g, 20%) as a light brown oil; MS (ESI): m / z=256.1 [M+H]+.

[0264] Step [B] 2-Chloro-3-(2-oxooxazolidin-3-yl)benzoic acid was prepared in the same manner as intermediate A-1[B] to give the title compound as an off-white solid. MS (ESI): m / z=242.0 [M+H] + .

[0265] Intermediate C-2 Lithium, 2-chloro-3-(2-oxoimidazolidin-1-yl)benzoate was prepared similarly to intermediate C-1, but in step [A], 1,3-dimethylurea was used to give the crude title compound as a white solid as the lithium salt; MS (ESI): m / z=241.1 [M+H] + .

[0266] Intermediates D-1a and D1-b 2-Bromo-3-[(Z)-styryl]benzoic acid and 2-Bromo-3-[(E)-styryl]benzoic acid

[0267] Step [A] (2-Bromo-3-methoxycarbonyl-phenyl)methyl-triphenyl-phosphonium; Bromide To a solution of triphenylphosphine (0.439 g, 1.67 mmol) in toluene (5 mL) was added methyl 2-bromo-3-(bromomethyl)benzoate (CAS RN 750585-90-1, 0.515 g, 1.67 mmol) and the reaction mixture was heated to 110° C. for 15 h. The solid precipitate was filtered off and washed three times with diethyl ether, then further dried to give the crude title compound as the hydrobromide salt (0.918 g) as a white solid; MS (ESI): m / z=491.1 [M+H] + .

[0268] Step [B] Methyl 2-bromo-3-[(Z)-styryl]benzoate and methyl 2-bromo-3-[(E)-styryl]benzoate To a suspension of (2-bromo-3-methoxycarbonyl-phenyl)methyl-triphenyl-phosphonium bromide (0.102 g, 0.207 mmol) in THF (10 mL) cooled to 0° C., potassium tert-butoxide (0.025 g, 0.226 mmol) was added and the mixture was stirred for 30 min. Then, benzaldehyde (0.019 mL, 0.188 mmol) in THF (5 mL) was added dropwise and the reaction mixture was stirred at room temperature for 4 h. The mixture was quenched with saturated aqueous NH4Cl solution and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with a 0-40% EtOAc-heptane gradient to give methyl 2-bromo-3-[(Z)-styryl]benzoate (0.013 g, 17%) and methyl 2-bromo-3-[(E)-styryl]benzoate (0.023 g, 38%), respectively, as yellow oils; MS (ESI): m / z=317.0 [M+H]+.

[0269] Step [C] 2-Bromo-3-[(Z)-styryl]benzoic acid To methyl (Z)-2-bromo-3-styrylbenzoate (0.113 g, 0.357 mmol) in THF (1 mL) was added 1M aqueous LiOH (0.219 mL, 0.219 mmol) and the reaction mixture was heated to 40° C. for 6 h. The reaction was neutralized with 2M aqueous HCl and extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo to give the crude title compound (D1a, 0.095 g, 87%) as a white solid; MS (ESI): m / z=303.1 [M+H] + .

[0270] Step [D] 2-Bromo-3-[(E)-styryl]benzoic acid was prepared similarly to step [C], but using methyl (E)-2-bromo-3-styrylbenzoate, to give the crude title compound (D1b, 85%) as a white solid; MS (ESI): m / z=303.1 [M+H] + .

[0271] Intermediate D-2 2-Bromo-3-[(E)-2-[4-(tert-butoxycarbonylamino)phenyl]vinyl]benzoic acid was prepared similarly to intermediate D-1b, except that in step [B], tert-butyl (4-formylphenyl)carbamate (CAS RN 144072-30-0) was used to give the crude title compound as a colorless oil; MS (ESI): m / z = 418.2 [M + H] + .

[0272] Intermediate D-3 2-Bromo-3-[(E)-2-(4-carboxyphenyl)vinyl]benzoic acid was prepared similarly to intermediate D-1b, except that in step [B], methyl 4-formylbenzoate (CAS RN 1571-08-0) was used to give the crude title compound as a colorless amorphous solid; MS (ESI): m / z = 346.9 [M+H] + .

[0273] Example 1 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone

[0274] In a flask, (7S,9aR)-7-(4-chlorophenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (Intermediate I-3A, 0.015 g, 0.053 mmol) and 2-chloro-3-methoxybenzoic acid (CAS RN 33234-36-5, 0.010 g, 0.055 mmol) were mixed in DMF (0.5 mL). Hunig's base (0.023 mL, 0.132 mmol) was then added followed by HATU (0.021 g, 0.055 mmol) and the reaction mixture was stirred at room temperature for 2 h. The crude mixture was purified by reverse phase HPLC to give the title compound (0.012 g, 50%) as a colorless amorphous solid; MS (ESI): m / z=453.2 [M+H] + .

[0275] The following examples listed in Table 2 were prepared similarly to the procedures described for the preparation of Example 1, using the indicated intermediates and / or commercially available compounds, and using purification methods previously described, such as reverse phase HPLC (Gemini NX column) or silica gel flash chromatography.

[0276] [Table 2] TIFF0007669299000056.tif215165 TIFF0007669299000057.tif215165 TIFF0007669299000058.tif215165 TIFF0007669299000059.tif215165 TIFF0007669299000060.tif215165 TIFF0007669299000061.tif220165 TIFF0007669299000062.tif204165 TIFF0007669299000063.tif215165 TIFF0007669299000064.tif220165 TIFF0007669299000065.tif220165 TIFF0007669299000066.tif220165 TIFF0007669299000067.tif226165 TIFF0007669299000068.tif225165 TIFF0007669299000069.tif231165 TIFF0007669299000070.tif220165 TIFF0007669299000071.tif225165 TIFF0007669299000072.tif216165 TIFF0007669299000073.tif225165

[0277] Example 23 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-piperazin-1-ylphenyl)methanone

[0278] To a solution of tert-butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate (Example 22, 0.023 g, 0.040 mmol) in DCM (0.5 mL) was added TFA (0.047 mL, 0.607 mmol) and the reaction mixture was stirred at room temperature for 6 h. The mixture was concentrated in vacuo, the residue was dissolved in EtOAc, poured into saturated aqueous NaHCO3, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and evaporated to dryness to give the crude title compound (0.017 g, 82%) as a yellow solid; MS (ESI): m / z = 473.3 [M+H] + .

[0279] Example 24 (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone

[0280] A suspension of cerium(III) chloride (0.092 g, 0.372 mmol) in THF (1 mL) was stirred at room temperature for 1.5 h. The mixture was cooled to 0 °C in an ice bath and a 2 M solution of isobutylmagnesium bromide in THF (0.155 mL, 0.310 mmol) was added dropwise and stirring was continued at this temperature for 1 h. Then a solution of 2-(2-chloro-3-methoxybenzoyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-7-one (intermediate I-5, 0.100 g, 0.310 mmol) in THF (0.3 mL) was added and the reaction mixture was stirred at 0 °C for 30 min. The mixture was quenched with water, filtered through Dicalite and washed with EtOAc. The resulting solution was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC to give the title compound (0.014, 12%) as an amorphous colorless solid; MS (ESI): m / z=381.3 [M+H] + .

[0281] Example 25 (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone was prepared similarly to Example 24, but using a 1 M solution of cyclopentylmagnesium bromide in THF to give the title compound as a pale yellow amorphous solid; MS (ESI): m / z=393.3 [M+H] + .

[0282] Example 26 (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone

[0283] In a three-necked round-bottom flask, a solution of 2-(2-chloro-3-methoxybenzoyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-7-one (Intermediate I-5, 0.1 g, 0.310 mmol) in THF (1.7 mL) was cooled to -5 °C with an ice-salt bath. Trimethyl(trifluoromethyl)silane (0.055 mL, 0.372 mmol) was added, and then after 10 min, a 1 M solution of TBAF (0.310 mL, 0.310 mmol) in THF was added to the mixture while keeping the temperature below 2 °C. The reaction mixture was stirred at 0 °C for an additional 10 min, then allowed to warm to room temperature and stirring was continued for 2 h. The mixture was quenched with saturated aqueous NH4Cl, and the mixture was diluted with EtOAc. The organic layer was washed with water, brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 50-100% EtOAc-heptane gradient to give the title compound (0.022 g, 18%) as a colorless solid; MS (ESI): m / z=393.2 [M+H] + .

[0284] Example 30 N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide

[0285] Step [A] [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[3-[(E)-2-(4-aminophenyl)vinyl]-2-bromo-phenyl]methanone To a solution of tert-butyl N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]carbamate (Example 29, 0.007 g, 0.011 mmol) in DCM (0.5 mL) was added TFA (0.017 mL, 0.222 mmol) and the reaction mixture was stirred at room temperature for 18 h. The mixture was concentrated in vacuo, the residue was dissolved in EtOAc, and the organic layer washed with saturated aqueous NaHCO3, washed with brine, dried over Na2SO4, filtered, and evaporated to dryness to give the crude title compound (0.008 g) as a yellow solid; MS (ESI): m / z = 550.1 [M+H] + .

[0286] Step [B] N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide To a solution of [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[3-[(E)-2-(4-aminophenyl)vinyl]-2-bromo-phenyl]methanone (0.008 g, 0.015 mmol) and acrylic acid (0.001 g, 0.015 mmol) in DMF (0.2 mL) was added Hunig's base (0.008 mL, 0.046 mmol) followed by HATU (0.006 g, 0.017 mmol) and the reaction mixture was stirred at room temperature for 15 h. The mixture was diluted with EtOAc, washed with water, brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC to give the title compound (0.005 g, 5%) as a colorless amorphous; MS (ESI): m / z=604.7 [M+H] + .

[0287] Example 31 4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide and 3-[(E)-2-[4-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]phenyl]vinyl]-2-bromo-N-methyl-benzamide

[0288] To a solution of 2-bromo-3-[(E)-2-(4-carboxyphenyl)vinyl]benzoic acid (Intermediate D-3, 0.04 g, 0.115 mmol) in DMF (0.5 mL), Hunig's base (0.05 mL, 0.288 mmol) was added and the mixture was stirred at room temperature for 1 h. Then, a mixture of methanamine hydrochloride (0.008 g, 0.115 mmol) and (7R,9aR)-7-(4-chlorophenyl)octahydro-1H-pyrido[1,2-a]pyrazine (Intermediate I-6, 0.029 g, 0.115 μmol) in DMF (0.5 mL) / Hunig's base (0.05 mL) was added dropwise and the reaction mixture was stirred at room temperature for 18 h. Water was added to the mixture, which was then batch-sonicated. The resulting precipitate was filtered off, collected, poured into 1M aqueous Na2CO3, and the aqueous layer was extracted with DCM. The organic layers were combined, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by silica gel flash chromatography eluting with a 0-5% MeOH-DCM gradient to give the title compound (0.032 g, 44%) as a 1:1 mixture of isomers as an off-white solid; MS (ESI): m / z=592.2 [M+H] + .

[0289] Example 65 [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone

[0290] Step [A] tert-Butyl 4-[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2,3-dihydroindole-1-carboxylate was prepared in the same manner as in Example 1, except that (7S,9aR)-7-(3-chloro-4-fluoro-phenyl)-1,2,3,4,6,8,9,9a-octahydropyrido[1,2-a]pyrazin-7-ol (Intermediate I-3A) and 1-tert-butoxycarbonylindoline-4-carboxylic acid (CAS RN 208774-11-2) were used to obtain the title compound as a colorless foam; MS (ESI): m / z=530.4 [M+H] + .

[0291] Step [B] [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone

[0292] To a solution of tert-butyl 4-[(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2,3-dihydroindole-1-carboxylate (0.03 g, 0.057 mmol) in DCM (0.5 mL) was added TFA (0.087 mL, 1.13 mmol) and the reaction mixture was stirred at room temperature for 2 h. The mixture was added dropwise to saturated aqueous NaHCO3 (5 mL) and the aqueous phase was extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and evaporated to dryness to give the title compound (0.007 g, 29%) as a colorless foam; MS (ESI): m / z = 430.3 [M+H] + .

[0293] Example 66 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone

[0294] In a sealed tube [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(5-bromo-4-chloropyridin-3-yl)methanone (Intermediate I-9, 0.023 g, 0.048 mmol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate (CAS RN 1256359-17-7, 0.017 g, 0.058 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.004 g, 0.005 mmol) were dissolved in DMF (0.25 mL). The reaction mixture was purged with argon. Then, a 1M aqueous solution of Na2CO3 (0.145 mL, 0.145 mmol) was added and the reaction mixture was heated to 90° C. overnight. The mixture was diluted with EtOAc, poured into water, and the aqueous layer was extracted with EtOAc. The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by reverse phase HPLC to give the title compound (0.003 g, 12%) as a colorless solid; MS (ESI): m / z=472.4 [M+H] + .

[0295] Example 67 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone

[0296] In a microwave vial, [3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chloro-phenyl]boronic acid (Intermediate I-7, 0.03 g, 0.067 mmol), 3-bromoisothiazole (CAS RN 55512-82-8, 0.01 g, 0.061 mmol), bis(di-tert-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium (CAS RN 887919-35-9, 0.004 g, 0.006 mmol) and KCO (0.025 g, 0.183 mmol) were mixed in dioxane (1.72 mL) and water (0.440 mL). The mixture was degassed with argon and heated to 90° C. in a microwave for 15 min. The mixture was diluted with EtOAc and washed with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse phase HPLC to give the title compound (0.005 g, 16%) as a colorless amorphous solid; MS (ESI): m / z=488.3 [M+H] + .

[0297] Example 68 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone was prepared similarly to Example 67, but using 4-bromoisothiazole (CAS RN 24340-77-0), to give the title compound as a colorless amorphous solid; MS (ESI): m / z=488.3 [M+H] + .

[0298] Example 69 [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone was prepared similarly to Example 67, but using 2-chloro-3-((7R,9aR)-7-hydroxy-7-(5-(trifluoromethyl)pyridin-2-yl)octahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)phenyl)boronic acid (Intermediate I-8) and bromoisothiazole (CAS RN 55512-82-8) to give the title compound as a colorless amorphous solid; MS (ESI): m / z=523.3 [M+H] + .

[0299] Example 70 [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone was prepared similarly to Example 66, but using [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(5-bromo-4-methylpyridin-3-yl)methanone (Intermediate I-11), to give the title compound as a colorless foam; MS (ESI): m / z=452.3 [M+H] + .

[0300] Example 71 and Example 72 (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone and (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone

[0301] To a suspension of 5-bromo-2-(trifluoromethyl)pyridine (CAS RN 436799-32-5, 0.12 g, 0.531 mmol) in toluene (4.2 mL) cooled to -78 °C, a 1.6 M solution of n-BuLi in hexane (0.398 mL, 0.637 mmol) was added and the mixture was stirred at this temperature for 5 min. Then a solution of 2-(2-chloro-3-methoxybenzoyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-7-one (intermediate I-5, 0.189 g, 0.584 mmol) was added dropwise at -78 °C and the reaction mixture was stirred at this temperature for 3 h. The mixture was quenched at -78 °C by adding saturated aqueous NH4Cl solution and extracted with EtOAc. The combined organic layers were washed with HO, brine, dried over NaSO, filtered and evaporated. The crude material was purified by silica gel flash chromatography eluting with a gradient of 20-60% EtOAc in heptane to give 65 mg of impure material including (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone (Example 71, 0.006 g, 2.4%) and the trans compound, respectively. The residue was purified by reverse phase HPLC to give (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone (Example 72, 0.004 g, 1.8%) as a colorless amorphous solid; MS (ESI): m / z=470.3 [M+H] + .

[0302] Example 73 The compounds of formula (I) can be used in a manner known per se as active ingredient to prepare tablets of the following composition:

[0303] Per tablet Active ingredient: 200mg Microcrystalline cellulose 155mg Cornstarch 25mg Talc 25mg Hydroxypropyl methylcellulose 20mg 425mg

[0304] Example 74 The compounds of formula (I) can be used in a manner known per se as active ingredient to prepare capsules of the following composition:

[0305] Per capsule Active ingredient 100.0mg Cornstarch 20.0mg Lactose 95.0mg Talc 4.5mg Magnesium stearate 0.5mg 220.0mg

Claims

1. Formula (I): 【Chemistry 41】 [In the formula: R １ teeth, (i) C １－６ -alkoxy, halogen and 【Chemistry 42】 C optionally substituted with 1 to 2 substituents independently selected from the group consisting of ６ -C １４ -aryl; (ii) halogen, C １－６ -Alkoxy, C １－６ - a 5-6 membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogen, C １－６ - 5-14 membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl and oxo; is selected from the group consisting of R ２ teeth, (i) C substituted with 1 to 3 substituents independently selected from halogen １－６ - alkyl; (ii) C ３－１４ -cycloalkyl; and (iii) halogen, C １－６ -Alkyl, halo-C １－６ - 5-14 membered heteroaryl optionally substituted with 1 to 3 substituents independently selected from alkyl, and oxo; is selected from the group consisting of R ３ is hydrogen, halogen, C １－６ -Alkoxy, C ３－１４ - selected from the group consisting of cycloalkyloxy and hydroxy; R ４ is hydrogen, halogen, C １－６ -Alkyl, C １－６ -alkoxycarbonyl, C １－６ -alkoxycarbonyl-NH-, hydroxy, amino, carboxy, C １－６ -alkyl-C(O)-NH-, C ２－６ -alkenyl-C(O)-NH-, carboxy-NH-, oxo, C ３－１４ -cycloalkyl and hydroxy-C ３－１４ -cycloalkyl, L is selected from the group consisting of a covalent bond and -CH=CH-; A is C ６ -C １４ - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1, 2, 3, or 4. or a pharma- ceutically acceptable salt thereof.

2. R １ but, (i) C １－６ -alkoxy, halogen and 【Chemistry 43】 C substituted with 1 to 2 substituents independently selected from the group consisting of ６ -C １４ -aryl; (ii) halogen, C １－６ -Alkoxy, C １－６ - a 5-6 membered heteroaryl optionally substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogen, C １－６ - 5-14 membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl and oxo; 2. The compound of formula (I) according to claim 1, selected from the group consisting of:

3. R １ But, C １－６ -alkoxy, halogen and 【Chemistry 44】 C substituted with 1 to 2 substituents independently selected from the group consisting of ６ -C １４ -aryl; or a pharma- ceutically acceptable salt thereof.

4. R １ Chloro, fluoro, methoxy and 【Chemistry 45】 or a pharma- ceutically acceptable salt thereof. The compound of formula (I) according to claim 1, wherein R is phenyl substituted with 1 to 2 substituents independently selected from the group consisting of:

5. R ２ but, (i) C substituted with 1 to 3 substituents independently selected from halogen １－６ - alkyl; (ii) C ３－１４ -cycloalkyl; and (iii) halo-C １－６ - 5-14 membered heteroaryl substituted with alkyl; 5. The compound of formula (I) according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

6. R ２ But, Hello-C １－６ 5. The compound of formula (I) according to any one of claims 1 to 4, wherein R is 5 to 14 membered heteroaryl substituted with -alkyl, or a pharma- ceutically acceptable salt thereof.

7. R ２ is CF ３ 5. The compound of formula (I) according to any one of claims 1 to 4, which is pyridyl substituted with -, or a pharma- ceutically acceptable salt thereof.

8. R ３ A compound of formula (I) according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen or hydroxy.

9. R ３ A compound of formula (I) according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, wherein is hydroxy.

10. R ４ But hydrogen, halogen, C １－６ -Alkyl, C １－６ -alkoxycarbonyl, C １－６ 10. The compound of formula (I) according to any one of claims 1 to 9, wherein -alkoxycarbonyl-NH-, hydroxy and oxo are selected from the group consisting of: -alkoxycarbonyl-NH-, hydroxy and oxo, or a pharma- ceutically acceptable salt thereof.

11. R ４ A compound of formula (I) according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, halogen and hydroxy.

12. R ４ A compound of formula (I) according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, wherein is selected from the group consisting of hydrogen, fluoro and hydroxy.

13. 13. A compound of formula (I) according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, wherein L is a covalent bond.

14. 14. The compound of formula (I) according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof, wherein A is selected from the group consisting of 5-14 membered heteroaryl and 5-14 membered heterocyclyl.

15. 14. The compound of formula (I) according to any one of claims 1 to 13, or a pharma- ceutically acceptable salt thereof, wherein A is selected from the group consisting of pyrazolyl and azetidinyl.

16. 16. A compound of formula (I) according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, wherein n is 1 or 2.

17. R １ but, (i) C １－６ -alkoxy, halogen and 【Chemistry 46】 C substituted with 1 to 2 substituents independently selected from the group consisting of ６ -C １４ -aryl; (ii) halogen, C １－６ -Alkoxy, C １－６ - a 5-6 membered heteroaryl substituted with 1-2 substituents independently selected from the group consisting of alkyl and amino; and (iii) halogen, C １－６ - 5-14 membered heterocyclyl optionally substituted with 1 to 3 substituents independently selected from the group consisting of alkyl and oxo; is selected from the group consisting of R ２ but, (i) C substituted with 1 to 3 substituents independently selected from halogen １－６ - alkyl; (ii) C ３－１４ -cycloalkyl; and (iii) halo-C １－６ - 5-14 membered heteroaryl substituted with alkyl; is selected from the group consisting of R ３ is hydrogen or hydroxy; R ４ But hydrogen, halogen, C １－６ -Alkyl, C １－６ -alkoxycarbonyl, C １－６ -alkoxycarbonyl-NH-, hydroxy and oxo; L is selected from the group consisting of a covalent bond and -CH=CH-; A is C ６ -C １４ - selected from the group consisting of aryl, 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1 or 2; 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof.

18. R １ But, C １－６ -alkoxy, halogen and 【Chemistry 47】 C substituted with 1 to 2 substituents independently selected from the group consisting of ６ -C １４ -aryl, R ２ But, Hello-C １－６ - 5-14 membered heteroaryl substituted with alkyl; R ３ is hydroxy, R ４ is selected from the group consisting of hydrogen, halogen and hydroxy; L is a covalent bond; A is selected from the group consisting of 5- to 14-membered heteroaryl, and 5- to 14-membered heterocyclyl; n is 1 or 2; 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof.

19. R １ is chloro, fluoro, methoxy, and 【Chemistry 48】 and is phenyl substituted with 1 to 2 substituents independently selected from the group consisting of: R ２ But, CF ３ pyridyl substituted with R ３ is hydroxy, R ４ is selected from the group consisting of hydrogen, fluoro and hydroxy; L is a covalent bond; A is selected from the group consisting of pyrazolyl and azetidinyl; n is 1 or 2; 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof.

20. below: [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aS)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone; [(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-fluoro-1H-pyrazol-4-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-6-methoxypyridin-3-yl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(6-amino-2-methylpyridin-3-yl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; 5-[(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one; 5-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-6-chloro-1-methylpyridin-2-one; 3-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]-1,3-oxazolidin-2-one; 1-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]imidazolidin-2-one; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-methyl-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[3-(4-methyl-1H-pyrazol-3-yl)phenyl]methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-morpholin-4-ylphenyl)methanone; tert-butyl 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-fluorophenyl]piperazine-1-carboxylate; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-fluoro-3-piperazin-1-ylphenyl)methanone; (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-(2-methylpropyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-cyclopentyl-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; (2-chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-(trifluoromethyl)-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(Z)-2-phenylethenyl]phenyl]methanone; [(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-yl]-[2-bromo-3-[(E)-2-phenylethenyl]phenyl]methanone; tert-butyl N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]carbamate; N-[4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromophenyl]ethenyl]phenyl]prop-2-enamide; and 4-[(E)-2-[3-[(7R,9aR)-7-(4-chlorophenyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine-2-carbonyl]-2-bromo-phenyl]vinyl]-N-methyl-benzamide or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

21. below: [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-hydroxyphenyl)methanone; 4-(3-((7S,9aR)-7-(4-chlorophenyl)-7-hydroxyoctahydro-2H-pyrido[1,2-a]pyrazine-2-carbonyl)-2-fluorophenyl)piperazin-2-one; 4-[3-[(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazine-2-carbonyl]-2-chlorophenyl]piperazin-2-one; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(6-oxa-1-azaspiro[3.3]heptan-1-yl)phenyl]methanone; [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(difluoromethoxy)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone; [(7S,9aS)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-fluorophenyl)methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxy-3-methylazetidin-1-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S)-3-hydroxypiperidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3R)-3-hydroxypiperidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-hydroxypiperidin-1-yl)phenyl]methanone; [2-chloro-3-(3-hydroxy-3-methylpyrrolidin-1-yl)phenyl]-[rac-(7R,9aS)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[(3S,4S)-3,4-dihydroxypyrrolidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-fluoro-3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-[3-(hydroxymethyl)azetidin-1-yl]phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1,2-thiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2,4-thiadiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7R,9aS)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2-chloro-3-methoxyphenyl)methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-fluoro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3,4-difluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(3-hydroxyazetidin-1-yl)phenyl]methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(4-fluoro-1H-pyrazol-5-yl)phenyl]methanone; [(7S,9aR)-7-(3-chloro-4-fluorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-(2,3-dihydro-1H-indol-4-yl)methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-chloro-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-4-yl)phenyl]methanone; [(7R,9aR)-7-hydroxy-7-[5-(trifluoromethyl)pyridin-2-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[2-chloro-3-(1,2-thiazol-3-yl)phenyl]methanone; [(7S,9aR)-7-(4-chlorophenyl)-7-hydroxy-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-[4-methyl-5-(1H-pyrazol-3-yl)pyridin-3-yl]methanone; (2-chloro-3-methoxyphenyl)-[rac-(7R,9aS)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone; and (2-Chloro-3-methoxyphenyl)-[rac-(7R,9aR)-7-hydroxy-7-[6-(trifluoromethyl)pyridin-3-yl]-3,4,6,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]methanone or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

22. A process for preparing a compound of formula (I) according to any one of claims 1 to 19, or a pharma- ceutically acceptable salt thereof, comprising the steps of: a) Amine 12 or 14: 【Chemistry 49】 [In the formula, R ２ is as defined in claim 1, R ３ is hydroxy (12) or hydrogen (14). of, Carboxylic Acid 15: 【Chemistry 50】 [In the formula, R １ is as defined in claim 1. and, Reacting in the presence of a coupling reagent and a base to form R ３ is hydroxy or hydrogen, and optionally ３ is hydroxy; b) R ３ Compounds of formula (I) in which R is hydroxy can be treated with base followed by the addition of a suitable electrophile to give R ３ is alkylated to give R ３ is alkoxy or cycloalkyloxy; or c) R ３ is hydroxy by reacting a compound of formula (I) with (i) a halogenating reagent; or (ii) with a sulfonylating reagent, followed by reacting the intermediate sulfonate with a halide to form R ３ is converted to a halogen, and R ３ is halogen. The process includes:

23. A compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, for use as a therapeutically active substance.

24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, and a therapeutically inert carrier.

25. 25. The pharmaceutical composition of claim 24 for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, and / or psychiatric disorders in a mammal.

26. 25. The pharmaceutical composition of claim 24 for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

27. 22. A compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, and / or psychiatric disorders in a mammal.

28. 22. A compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

29. 22. Use of a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt thereof for the preparation of a medicament for the treatment or prevention of neuroinflammation, neurodegenerative diseases, pain, cancer, and / or psychiatric disorders in a mammal.

30. 22. Use of a compound according to any one of claims 1 to 21 or a pharma- ceutically acceptable salt thereof for the preparation of a medicament for the treatment or prevention of multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or spasticity associated with pain in a mammal.

Images